JPH0137400B2 - - Google Patents
Info
- Publication number
- JPH0137400B2 JPH0137400B2 JP60111321A JP11132185A JPH0137400B2 JP H0137400 B2 JPH0137400 B2 JP H0137400B2 JP 60111321 A JP60111321 A JP 60111321A JP 11132185 A JP11132185 A JP 11132185A JP H0137400 B2 JPH0137400 B2 JP H0137400B2
- Authority
- JP
- Japan
- Prior art keywords
- resin
- amino
- alanine
- cells
- protected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 113
- 229920005989 resin Polymers 0.000 claims description 55
- 239000011347 resin Substances 0.000 claims description 55
- 229940024606 amino acid Drugs 0.000 claims description 39
- 125000006239 protecting group Chemical group 0.000 claims description 35
- 235000001014 amino acid Nutrition 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- -1 amino-protected L-isoleucine Chemical class 0.000 claims description 18
- 125000003277 amino group Chemical group 0.000 claims description 16
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 15
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 11
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 229960003767 alanine Drugs 0.000 claims description 7
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- 229930182844 L-isoleucine Natural products 0.000 claims description 5
- 229960001230 asparagine Drugs 0.000 claims description 5
- 235000018977 lysine Nutrition 0.000 claims description 5
- 229960004441 tyrosine Drugs 0.000 claims description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 235000019766 L-Lysine Nutrition 0.000 claims description 3
- 229930182816 L-glutamine Natural products 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000002952 polymeric resin Substances 0.000 claims 3
- 229920003002 synthetic resin Polymers 0.000 claims 3
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 87
- 229920001184 polypeptide Polymers 0.000 description 82
- 210000004027 cell Anatomy 0.000 description 26
- 210000001541 thymus gland Anatomy 0.000 description 25
- 210000003719 b-lymphocyte Anatomy 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 230000004069 differentiation Effects 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000002243 precursor Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 210000000115 thoracic cavity Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 101150052863 THY1 gene Proteins 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 210000004907 gland Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 102000006834 complement receptors Human genes 0.000 description 4
- 108010047295 complement receptors Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansÀure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 description 2
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 2
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000898 Thymopoietin Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000005332 diethylamines Chemical class 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- SHDMMLFAFLZUEV-UHFFFAOYSA-N n-methyl-1,1-diphenylmethanamine Chemical compound C=1C=CC=CC=1C(NC)C1=CC=CC=C1 SHDMMLFAFLZUEV-UHFFFAOYSA-N 0.000 description 2
- 208000018360 neuromuscular disease Diseases 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- LDQAVQLJHUEMEY-JTQLQIEISA-N (2s)-2-(ethylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical class CCN[C@H](C(O)=O)CC1=CC=C(O)C=C1 LDQAVQLJHUEMEY-JTQLQIEISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical group CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- UFBURHXMKFQVLM-CIUDSAMLSA-N Arg-Glu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UFBURHXMKFQVLM-CIUDSAMLSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
- JWNZHMSRZXXGTM-XKBZYTNZSA-N Glu-Ser-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JWNZHMSRZXXGTM-XKBZYTNZSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- VFBZWZXKCVBTJR-SRVKXCTJSA-N His-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VFBZWZXKCVBTJR-SRVKXCTJSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex⢠Substances 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000984 branchial region Anatomy 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical group S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 125000006286 dichlorobenzyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000001538 myasthenic effect Effects 0.000 description 1
- TXOUDPQJASQYBZ-UHFFFAOYSA-N n,n'-dihexylmethanediimine Chemical compound CCCCCCN=C=NCCCCCC TXOUDPQJASQYBZ-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯æ°èŠãªããªããããé¡ãæ°èŠãªããªã
ãããé¡ã®è£œé æ¹æ³ãåã³åèšããªããããé¡ã®
çšéã«é¢ããã
ãããé¡ã®è£œé æ¹æ³ãåã³åèšããªããããé¡ã®
çšéã«é¢ããã
å€ãã®ããªããããé¡ãåç©ã®åçš®åšç®¡ããå
é¢ãããŠããããšã¯ããç¥ãããŠãããããããª
ãããçŽ10幎åãŸã§ã¯çãŸãã人éã®äœéã®çŽ
0.8ïŒ ããããåšå®ã§ããèžç·ã«ã€ããŠã¯æ®ãã©
ç¥ããšããããªããå ãã«ç¥çµçé®æç©è³ªãèžç·
ã«ååšããŠãããšããä»®èšãæåºãããŠããã«ã
ããªããèžç·ã®æ©èœã«é¢ãã匷ãé¢å¿ãšåæã®æš
è«åã³å®éšã«ãæãããæè¿ãŸã§èžç·ã®æ©èœã«é¢
ããŠã¯æ®ãã©åã€ãŠããªãã€ããããããªããã
çŸåšã¯èžç·ã¯äžç®ïŒå åæ³ïŒæåãšãªã³ãïŒå ç«
åŠçïŒæåãšãæããè€åšå®ã§ããåŸã€ãŠèžç·ã¯
身äœã®å ç«æ©èœã«é¢äžããŠããããšãåã€ããå³
ã¡ãèžç·ã¯ç¬¬ïŒé°åŒã«ç±æ¥ããäžç®ã¹ãããåã³
é è¡çµç¹ã®å¹¹çŽ°èã«ç±æ¥ãããªã³ãçãããªãè€
åšã§ããããšã¯å ¬ç¥ã§ããïŒGoldsteinçã®
ãThe Human ThymusãïŒHeinemannïŒ
LondonïŒ1969幎åç §ïŒããªã³ãçã¯èžç·å éšã§å
åãããŠïŒŽçŽ°èãšèšãããæçããèžç·ç±æ¥çŽ°è
ãšããŠèžç·ããé¢ããè¡æ¶²ããªã³ããèŸèããªã³
ãç¯ãžãšåŸªç°ãããèžç·å éšã§ã®å¹¹çŽ°èååã®èª
å°ã¯èžç·ã®äžç®çŽ°èã®åæ³ç©ãåªä»ãšããŠèµ·ãã
ãã«æãããããçç©è©Šéšã«äŒŽãçš®ã ã®å°é£ã«ã
ãååšãããšèãããããã«ã¢ã³é¡ã®å®å šãªåé¢
åã³æ§é ã®ç¹å®ãã§ããªãã€ããšããã®ããããŸ
ã§ã®å®æ ã§ãã€ãã
é¢ãããŠããããšã¯ããç¥ãããŠãããããããª
ãããçŽ10幎åãŸã§ã¯çãŸãã人éã®äœéã®çŽ
0.8ïŒ ããããåšå®ã§ããèžç·ã«ã€ããŠã¯æ®ãã©
ç¥ããšããããªããå ãã«ç¥çµçé®æç©è³ªãèžç·
ã«ååšããŠãããšããä»®èšãæåºãããŠããã«ã
ããªããèžç·ã®æ©èœã«é¢ãã匷ãé¢å¿ãšåæã®æš
è«åã³å®éšã«ãæãããæè¿ãŸã§èžç·ã®æ©èœã«é¢
ããŠã¯æ®ãã©åã€ãŠããªãã€ããããããªããã
çŸåšã¯èžç·ã¯äžç®ïŒå åæ³ïŒæåãšãªã³ãïŒå ç«
åŠçïŒæåãšãæããè€åšå®ã§ããåŸã€ãŠèžç·ã¯
身äœã®å ç«æ©èœã«é¢äžããŠããããšãåã€ããå³
ã¡ãèžç·ã¯ç¬¬ïŒé°åŒã«ç±æ¥ããäžç®ã¹ãããåã³
é è¡çµç¹ã®å¹¹çŽ°èã«ç±æ¥ãããªã³ãçãããªãè€
åšã§ããããšã¯å ¬ç¥ã§ããïŒGoldsteinçã®
ãThe Human ThymusãïŒHeinemannïŒ
LondonïŒ1969幎åç §ïŒããªã³ãçã¯èžç·å éšã§å
åãããŠïŒŽçŽ°èãšèšãããæçããèžç·ç±æ¥çŽ°è
ãšããŠèžç·ããé¢ããè¡æ¶²ããªã³ããèŸèããªã³
ãç¯ãžãšåŸªç°ãããèžç·å éšã§ã®å¹¹çŽ°èååã®èª
å°ã¯èžç·ã®äžç®çŽ°èã®åæ³ç©ãåªä»ãšããŠèµ·ãã
ãã«æãããããçç©è©Šéšã«äŒŽãçš®ã ã®å°é£ã«ã
ãååšãããšèãããããã«ã¢ã³é¡ã®å®å šãªåé¢
åã³æ§é ã®ç¹å®ãã§ããªãã€ããšããã®ããããŸ
ã§ã®å®æ ã§ãã€ãã
èžç·ã¯èº«äœã®å
ç«ç¹æ§ã«é¢é£ãããããšãåã€
ãŠããã®ã§èžç·ããåé¢ãããç©è³ªã«å€å€§ã®é¢å¿
ãåããããŠãããè¿å¹Žãçã®èžç·ã«ååšããç©
質ã«é¢ããç§åŠçç 究ã«åºã¥ãæ¯èŒç倧éšã®è«æ
éãçºè¡šãããŠãããçŸã«æ¬åºé¡äººãäžèšåéã®
ç 究ã«é¢ããå€æ°ã®è«æãçºè¡šããŠãããé¢é£ã
ãåè¡ç©ãšããŠã¯ãäŸãã°ããThe LancetãïŒ
1968幎ïŒæ20æ¥å·ãp119â122ïŒãTriangleãïŒ
VolïŒ11ïŒNo.ïŒïŒp.7â14ïŒ1972ïŒãAnnals of
the New York Academy ImmunologyãïŒ
Vol.4ïŒNo.ïŒïŒp.181â189ïŒ1969ïŒïŒ»NatureãïŒ
Vol.247.p.11â14ïŒ1974ïŒãProceedings of the
National Academy of ScienceïŒUSAãïŒ
Vol.71ïŒp.1474â1478ïŒ1974ïŒãCellãïŒVol.5ïŒ
p.361â365åã³367â370ïŒ1975ãLancetãïŒVol.2ïŒ
p.256â259ïŒ1975ïŒãProceedings of the
National Academy of Sciences USAãïŒVol.72ïŒp.11
â15ïŒ1975ïŒãBiochemistryãïŒVol.14ïŒp.2214â
2218ïŒ1974ïŒãNatureãïŒVol.255.p.423â
424.1975ïŒãããã
ãŠããã®ã§èžç·ããåé¢ãããç©è³ªã«å€å€§ã®é¢å¿
ãåããããŠãããè¿å¹Žãçã®èžç·ã«ååšããç©
質ã«é¢ããç§åŠçç 究ã«åºã¥ãæ¯èŒç倧éšã®è«æ
éãçºè¡šãããŠãããçŸã«æ¬åºé¡äººãäžèšåéã®
ç 究ã«é¢ããå€æ°ã®è«æãçºè¡šããŠãããé¢é£ã
ãåè¡ç©ãšããŠã¯ãäŸãã°ããThe LancetãïŒ
1968幎ïŒæ20æ¥å·ãp119â122ïŒãTriangleãïŒ
VolïŒ11ïŒNo.ïŒïŒp.7â14ïŒ1972ïŒãAnnals of
the New York Academy ImmunologyãïŒ
Vol.4ïŒNo.ïŒïŒp.181â189ïŒ1969ïŒïŒ»NatureãïŒ
Vol.247.p.11â14ïŒ1974ïŒãProceedings of the
National Academy of ScienceïŒUSAãïŒ
Vol.71ïŒp.1474â1478ïŒ1974ïŒãCellãïŒVol.5ïŒ
p.361â365åã³367â370ïŒ1975ãLancetãïŒVol.2ïŒ
p.256â259ïŒ1975ïŒãProceedings of the
National Academy of Sciences USAãïŒVol.72ïŒp.11
â15ïŒ1975ïŒãBiochemistryãïŒVol.14ïŒp.2214â
2218ïŒ1974ïŒãNatureãïŒVol.255.p.423â
424.1975ïŒãããã
Goldsteinåã³Manganaroã«ãããAnnals of
the New York Academy of SciencesãïŒ
Vol.183ïŒp.230â240ïŒ1971ã®è«æã«ã¯ãåç©ã®
çç¡åçç¥çµçé害ãåŒèµ·ãèžç·ããªããããã®
ååšãé瀺ãããŠããããã®ç¥çµçé害ã¯äººéã®
ç æ°ã§ããéçæ§çç¡åçã«äŒŒããã®ã§ãããæŽ
ã«äžèšè«æã«ã¯ãçã®èžç·ã«å«ãŸããäžèšã«ç€ºã
ããšå¥ã®ããªããããé¡ã«ããïŒã€ã®å¹æãçã
ãããšã瀺ãããŠããããããã®ããªããããé¡
ã®ïŒã€ã¯ãã¢ããã·ã³ïŒThymotoxinïŒãšåä»ã
ãããŠãããã®ã§ãããã¯ççãåŒèµ·ããšæãã
ãŠããããã®ããªããããã¯åé¢ãããŠããªã
ããååéçŽ7000ã§ãããšæããã匷éœé»è·ãæ
ããã€PH8.0ã§CMâã»ãã¢ããã¯ã¹ïŒCMâ
SephadexïŒã«ä¿æãããããšãåèšè«æã«ç€ºã
ããŠããã
the New York Academy of SciencesãïŒ
Vol.183ïŒp.230â240ïŒ1971ã®è«æã«ã¯ãåç©ã®
çç¡åçç¥çµçé害ãåŒèµ·ãèžç·ããªããããã®
ååšãé瀺ãããŠããããã®ç¥çµçé害ã¯äººéã®
ç æ°ã§ããéçæ§çç¡åçã«äŒŒããã®ã§ãããæŽ
ã«äžèšè«æã«ã¯ãçã®èžç·ã«å«ãŸããäžèšã«ç€ºã
ããšå¥ã®ããªããããé¡ã«ããïŒã€ã®å¹æãçã
ãããšã瀺ãããŠããããããã®ããªããããé¡
ã®ïŒã€ã¯ãã¢ããã·ã³ïŒThymotoxinïŒãšåä»ã
ãããŠãããã®ã§ãããã¯ççãåŒèµ·ããšæãã
ãŠããããã®ããªããããã¯åé¢ãããŠããªã
ããååéçŽ7000ã§ãããšæããã匷éœé»è·ãæ
ããã€PH8.0ã§CMâã»ãã¢ããã¯ã¹ïŒCMâ
SephadexïŒã«ä¿æãããããšãåèšè«æã«ç€ºã
ããŠããã
ãNatureãïŒ247ïŒ11.1975幎ïŒæïŒæ¥å·ã«ã¯ã
ããã³ïŒThyminïŒåã³ããã³ïŒThymin
ïŒãšåå®ãããç©è³ªãèšèŒãããŠãããããã
ã®ç©è³ªã¯çã®èžç·ããåé¢ãããæ°ããªãããã
é¡ã§ãããçš®ã ã®æ²»çåéã«ç¹å®ã®çšéãæãã
ããšãèŠåºããããéå»ãçã®èžç·ããåé¢ãã
ãä»ã®ç©è³ªã«å¯ŸããŠãåæ§ã®å称ãçšããããŠã
ãã®ã§ãããã³åã³ç©è³ªã¯çŸåšãã¢ãã€ãšã
ã³ïŒThymopoietinïŒåã³ãã¢ãã€ãšãã³
ïŒThymopoietinïŒãšããããåŒç§°ãããŠããã
ãããã®ç©è³ªåã³ãã®è£œé æ³ã¯1975幎ïŒæ22æ¥ä»
ã§ç±³åœã«åºé¡ãããç±³åœç¹èš±åºé¡ç¬¬606843å·æ现
æžã«èšèŒãããŠããã
ããã³ïŒThyminïŒåã³ããã³ïŒThymin
ïŒãšåå®ãããç©è³ªãèšèŒãããŠãããããã
ã®ç©è³ªã¯çã®èžç·ããåé¢ãããæ°ããªãããã
é¡ã§ãããçš®ã ã®æ²»çåéã«ç¹å®ã®çšéãæãã
ããšãèŠåºããããéå»ãçã®èžç·ããåé¢ãã
ãä»ã®ç©è³ªã«å¯ŸããŠãåæ§ã®å称ãçšããããŠã
ãã®ã§ãããã³åã³ç©è³ªã¯çŸåšãã¢ãã€ãšã
ã³ïŒThymopoietinïŒåã³ãã¢ãã€ãšãã³
ïŒThymopoietinïŒãšããããåŒç§°ãããŠããã
ãããã®ç©è³ªåã³ãã®è£œé æ³ã¯1975幎ïŒæ22æ¥ä»
ã§ç±³åœã«åºé¡ãããç±³åœç¹èš±åºé¡ç¬¬606843å·æ现
æžã«èšèŒãããŠããã
ç±³åœç¹èš±ç¬¬4002602å·æ现æžã«ã¯ãéåšæ§é å
ç«æ§ããªããããïŒUbiquitous Immunopoietic
PolypeptideïŒãšããŠèšèŒãããŠããé·éããªã
ãããé¡ãé瀺ãããŠããããã®ããªããããã¯
åŸã«ãŠãããã³ïŒUbiquitinïŒãšåä»ãããããã
74âã¢ããé žããªããããã§ããè©Šéšç®¡äžããã°
ã©ã åäœã®æ¿åºŠã§éªšé«åã¯èŸèã«ååšããå é§ç©
質ãã现èåã³ïŒ¢çŽ°èã®å ç«çŽ°èã®ååãèªå°
ããèœåãç¹åŸŽãšãããã®ã§ãããåŸã€ãŠãäžèš
ããªããããã¯èžç·åã¯å ç«æ¬ é¥åã¯æ¬ 倱çã®æ²»
çåéã«æå¹ã§ããã
ç«æ§ããªããããïŒUbiquitous Immunopoietic
PolypeptideïŒãšããŠèšèŒãããŠããé·éããªã
ãããé¡ãé瀺ãããŠããããã®ããªããããã¯
åŸã«ãŠãããã³ïŒUbiquitinïŒãšåä»ãããããã
74âã¢ããé žããªããããã§ããè©Šéšç®¡äžããã°
ã©ã åäœã®æ¿åºŠã§éªšé«åã¯èŸèã«ååšããå é§ç©
質ãã现èåã³ïŒ¢çŽ°èã®å ç«çŽ°èã®ååãèªå°
ããèœåãç¹åŸŽãšãããã®ã§ãããåŸã€ãŠãäžèš
ããªããããã¯èžç·åã¯å ç«æ¬ é¥åã¯æ¬ 倱çã®æ²»
çåéã«æå¹ã§ããã
1977幎ïŒæ11æ¥ä»ã§çºè¡ãããç±³åœç¹èš±ç¬¬
4002740å·ã¯æ现æžã«ã¯ãåæããªãã«ãããã
çµæç©ãé瀺ãããŠããããããã®ããªãã«ãã
ããçµæç©ã¯è£äœå容äœã§ããâãªã³ãçã§ã¯
ãªãâãªã³ãçã®ååãèªå°ããããšãã§ã
ããåŸã€ãŠããã®ããªããããã¯äžè¿°ç±³åœç¹èš±åº
é¡ç¬¬606843å·æ现æžã«æŒããŠãã¢ãã€ãšãã¬ã³ãš
ããŠåé¢ãããé·éããªããããé¡ã®ç¹æ§ã®å å€
ãã®ãã®ããã®ç¹æ§ãšããŠç€ºããã
4002740å·ã¯æ现æžã«ã¯ãåæããªãã«ãããã
çµæç©ãé瀺ãããŠããããããã®ããªãã«ãã
ããçµæç©ã¯è£äœå容äœã§ããâãªã³ãçã§ã¯
ãªãâãªã³ãçã®ååãèªå°ããããšãã§ã
ããåŸã€ãŠããã®ããªããããã¯äžè¿°ç±³åœç¹èš±åº
é¡ç¬¬606843å·æ现æžã«æŒããŠãã¢ãã€ãšãã¬ã³ãš
ããŠåé¢ãããé·éããªããããé¡ã®ç¹æ§ã®å å€
ãã®ãã®ããã®ç¹æ§ãšããŠç€ºããã
æ¬çºæã¯äžå®ã®æŽ»æ§éšæ§é åäœãæããåæïŒ
âã¢ããé žããªããããã補é ããæ¹æ³ã§ããã
ãã®ããªããããã¯äžè¿°åè¡ç©åã³ç±³åœç¹èš±ç¬¬
4002602å·æ现æžã«æŒããŠéåšæ§é å ç«æ§ããªã
ãããïŒUBIPïŒãšããŠåé¢ãããé·éããªãã
ããã®æã€å€ãã®ç¹æ§ããã®ç¹æ§ãšããŠç€ºãããš
ãåã€ãã
âã¢ããé žããªããããã補é ããæ¹æ³ã§ããã
ãã®ããªããããã¯äžè¿°åè¡ç©åã³ç±³åœç¹èš±ç¬¬
4002602å·æ现æžã«æŒããŠéåšæ§é å ç«æ§ããªã
ãããïŒUBIPïŒãšããŠåé¢ãããé·éããªãã
ããã®æã€å€ãã®ç¹æ§ããã®ç¹æ§ãšããŠç€ºãããš
ãåã€ãã
åŸã€ãŠãæ¬çºæã®ç®çã¯çç©åŠçã«éèŠã§ãã
æ°èŠãªããªããããé¡ã®è£œæ³ãæäŸããããšã§ã
ãã
æ°èŠãªããªããããé¡ã®è£œæ³ãæäŸããããšã§ã
ãã
æ¬çºæã®ä»ã®ç®çã¯ããã°ã©ã åäœã®æ¿åºŠã§ïŒ¢
âå é§äœçŽ°èãšïŒŽâå é§äœçŽ°èãšãååã§ããåŸ
ã€ãŠäººéåã³åç©ã®å ç«ç³»ã«éåžžã«æå¹ã§ããæ°
èŠãªããªããããé¡ã®è£œæ³ãæäŸããããšã§ã
ãã
âå é§äœçŽ°èãšïŒŽâå é§äœçŽ°èãšãååã§ããåŸ
ã€ãŠäººéåã³åç©ã®å ç«ç³»ã«éåžžã«æå¹ã§ããæ°
èŠãªããªããããé¡ã®è£œæ³ãæäŸããããšã§ã
ãã
以äžãæ¬çºæãæŽã«è©³ãã説æããã
æ¬çºæã®æ¹æ³ã«ããæ°èŠãªããªããããé¡ã¯æŽ»
æ§éšäœåã¯æåãšããŠäžèšæ§é åäœãæãããã®
ã§ããã
æ§éšäœåã¯æåãšããŠäžèšæ§é åäœãæãããã®
ã§ããã
ââââGLNâLYSâ
äžåŒã«æŒããŠãã¯TYRïŒïŒ¹ã¯ASNïŒïŒºã¯
ILEãè¡šããã
ILEãè¡šããã
æŽã«ãæ¬çºæã«ãããŠã¯åèšããªããããã®è£œ
é éçšã§åœ¢æãããæ°èŠãªããªããããâæš¹èäž
éäœãçãããã®ã§ããããã®äžéäœã¯äžèšåŒã§
è¡šããããã
é éçšã§åœ¢æãããæ°èŠãªããªããããâæš¹èäž
éäœãçãããã®ã§ããããã®äžéäœã¯äžèšåŒã§
è¡šããããã
äžèšåŒã«æŒããŠãïŒïŒ¹åã³ïŒºã¯åè¿°ã®éãã§
ãããR1ïŒR2åã³R3ã¯ãå¿ èŠã«ããããããã
瀺ãããŠããåã¢ããé žã«çµåããŠããä¿è·åºã§
ãããæš¹èã¯åå¿æ¯æäœãšããŠäœçšããåºçžé«å
åç©è³ªã§ãããæ¬çºæã¯åºæ ããããåææ³ã«ã
ãããªããããã®è£œæ³ã§ããã
ãããR1ïŒR2åã³R3ã¯ãå¿ èŠã«ããããããã
瀺ãããŠããåã¢ããé žã«çµåããŠããä¿è·åºã§
ãããæš¹èã¯åå¿æ¯æäœãšããŠäœçšããåºçžé«å
åç©è³ªã§ãããæ¬çºæã¯åºæ ããããåææ³ã«ã
ãããªããããã®è£œæ³ã§ããã
äžè¿°ã®åŠããæ¬çºæã¯çš®ã
ã®åéã«æ²»çå¹æã
æããæ°èŠãªããªããããé¡ãããªããããé¡ã®
補é éçšã§çããçš®ã ã®äžéäœãæ²»ççšçµæç©ã
åèšããªããããé¡ãå©çšããçšéãåã³ããªã
ãããé¡ã®è£œé æ¹æ³ã«é¢ãããã®ã§ããã
æããæ°èŠãªããªããããé¡ãããªããããé¡ã®
補é éçšã§çããçš®ã ã®äžéäœãæ²»ççšçµæç©ã
åèšããªããããé¡ãå©çšããçšéãåã³ããªã
ãããé¡ã®è£œé æ¹æ³ã«é¢ãããã®ã§ããã
æ¬çºæã®åèäŸã«ããã°ã掻æ§éšäœãšããŠäžèš
ã¢ããé žæ§é åäœãæããããªããããé¡ãåŸã
ããšãã§ããã
ã¢ããé žæ§é åäœãæããããªããããé¡ãåŸã
ããšãã§ããã
âââGLNâLYS
äžåŒã«æŒããŠãã¯TYRãã¯ASNãåã³ïŒº
ã¯ILEã§ããããšã奜ãŸããã
ã¯ILEã§ããããšã奜ãŸããã
æŽã«ã掻æ§éšäœãšããŠäžèšæ§é äœãå«ããã®ã§
ãã€ãŠäžèšäžè¬åŒã§è¡šãããããã³ã¿ããªããã
ããæäŸãããŠããã
ãã€ãŠäžèšäžè¬åŒã§è¡šãããããã³ã¿ããªããã
ããæäŸãããŠããã
äžåŒã§ãïŒïŒ¹åã³ïŒºã¯äžè¿°ã®éãã§ããã
åã³Râ²ã¯ãããããã³ã¿ããããæ§é äœã«çµå
ããŠãã眮æäœã§ããããããã®çœ®æäœã¯ã¢ãã
é žã®åºæ¬åœ¢æŽ»æ§æ§é äœã®çååŠç掻æ§ã«å®è³ªäžåœ±
é¿ãäžããªããã®ã§ãããåŒïŒïŒã®æå³ãããš
ããã¯ããããã®ïŒã€ã®æ«æºã¢ããé žã«ãã³ã¿ã
ãããååã®çååŠç掻æ§ã«å®è³ªçãªåœ±é¿ãåãŒ
ããªãå®èœåºåã¯èªå°äœïŒå³ã¡ãåã³Râ²ïŒã
çµåãããããšã«ãããã®ãã³ã¿ããããé¡ã®æ«
端ã¢ããé žãæ¹è³ªããããšãã§ãããšããããšã§
ãããåŸã€ãŠãæ«ç«¯ã¢ããé žåºåã³ã«ã«ãã³é žåº
ã¯æãçš®ã®ããªããããé¡ã®å Žåãšåæ§ã«ãã¿ã
ãããã®çååŠç掻æ§ä»äžã«é¢ããŠå¿ é ã®ãã®ã§
ãªããšããããšã§ããã
åã³Râ²ã¯ãããããã³ã¿ããããæ§é äœã«çµå
ããŠãã眮æäœã§ããããããã®çœ®æäœã¯ã¢ãã
é žã®åºæ¬åœ¢æŽ»æ§æ§é äœã®çååŠç掻æ§ã«å®è³ªäžåœ±
é¿ãäžããªããã®ã§ãããåŒïŒïŒã®æå³ãããš
ããã¯ããããã®ïŒã€ã®æ«æºã¢ããé žã«ãã³ã¿ã
ãããååã®çååŠç掻æ§ã«å®è³ªçãªåœ±é¿ãåãŒ
ããªãå®èœåºåã¯èªå°äœïŒå³ã¡ãåã³Râ²ïŒã
çµåãããããšã«ãããã®ãã³ã¿ããããé¡ã®æ«
端ã¢ããé žãæ¹è³ªããããšãã§ãããšããããšã§
ãããåŸã€ãŠãæ«ç«¯ã¢ããé žåºåã³ã«ã«ãã³é žåº
ã¯æãçš®ã®ããªããããé¡ã®å Žåãšåæ§ã«ãã¿ã
ãããã®çååŠç掻æ§ä»äžã«é¢ããŠå¿ é ã®ãã®ã§
ãªããšããããšã§ããã
ãããã®å®èœåºã®çœ®æãšããŠã¯éé¢ã¢ããåºã®
ã¢ã·ã«ååã³éé¢ã«ã«ãã³é žåºã®ã¢ããåã®ãã
ãªéåžžã®çœ®æãåã³ä»ã®ã¢ããé žé¡ã®çœ®æãå«ãŸ
ããããããã®èŠ³ç¹ããèŠãæãæ¬çºæã®ãã³ã¿
ããããé¡ã¯ç¹ç°ãªãã®ã§ãããšæããããäœæ
ãªããæ¬çºæã®ãã³ã¿ããããé¡ã¯åèšãããã
æ§é åäœããã®äžéšãšããŠå«ãåé倩ç¶ãããã
é¡ãšåãçååŠæŽ»æ§ã瀺ãããã§ãããããæ ã
ããããååã®çååŠç掻æ§ã¯ååã®ç«äœååŠç
ç¹åŸŽãå³ã¡ååã®ç¹å®ãªæãããã¿æ§é ã«èµ·å ã
ãŠãããšæããããããªããããã®çµåã¯åçŽã§
ãªãæè»ã§ãããã€ã·ãŒãç¶ããããç¶çã®åœ¢ç¶
ã§ååšããŠããããã®çµæãååå šäœãšããŠã¯æ
è»ãšãªãäžå®ã®ç¶æ ã§æãéãªã€ãŠãããæ¬çºæ
è ã¯æ¬çºæã®ãã³ã¿ããããã¯é·éã®å€©ç¶ããªã
ããããšåæ§ãªæãéãªãæ§é ãæãããæ åæ§
ã®çååŠçç¹æ§ã瀺ãããšãèŠåºããããã®æ§ãª
èš³ã§ãå®è³ªäžçååŠç掻æ§ã«åœ±é¿ãäžããªã眮æ
åºã§ãããåã¯ãã³ã¿ããããã®ååã®å€©ç¶éç³
æ§é ãé»å®³ããªã眮æåºã§ããã°ãã³ã¿ãããã
ã¯çš®ã ã®å®èœåºã§çœ®æããããšãã§ããã
ã¢ã·ã«ååã³éé¢ã«ã«ãã³é žåºã®ã¢ããåã®ãã
ãªéåžžã®çœ®æãåã³ä»ã®ã¢ããé žé¡ã®çœ®æãå«ãŸ
ããããããã®èŠ³ç¹ããèŠãæãæ¬çºæã®ãã³ã¿
ããããé¡ã¯ç¹ç°ãªãã®ã§ãããšæããããäœæ
ãªããæ¬çºæã®ãã³ã¿ããããé¡ã¯åèšãããã
æ§é åäœããã®äžéšãšããŠå«ãåé倩ç¶ãããã
é¡ãšåãçååŠæŽ»æ§ã瀺ãããã§ãããããæ ã
ããããååã®çååŠç掻æ§ã¯ååã®ç«äœååŠç
ç¹åŸŽãå³ã¡ååã®ç¹å®ãªæãããã¿æ§é ã«èµ·å ã
ãŠãããšæããããããªããããã®çµåã¯åçŽã§
ãªãæè»ã§ãããã€ã·ãŒãç¶ããããç¶çã®åœ¢ç¶
ã§ååšããŠããããã®çµæãååå šäœãšããŠã¯æ
è»ãšãªãäžå®ã®ç¶æ ã§æãéãªã€ãŠãããæ¬çºæ
è ã¯æ¬çºæã®ãã³ã¿ããããã¯é·éã®å€©ç¶ããªã
ããããšåæ§ãªæãéãªãæ§é ãæãããæ åæ§
ã®çååŠçç¹æ§ã瀺ãããšãèŠåºããããã®æ§ãª
èš³ã§ãå®è³ªäžçååŠç掻æ§ã«åœ±é¿ãäžããªã眮æ
åºã§ãããåã¯ãã³ã¿ããããã®ååã®å€©ç¶éç³
æ§é ãé»å®³ããªã眮æåºã§ããã°ãã³ã¿ãããã
ã¯çš®ã ã®å®èœåºã§çœ®æããããšãã§ããã
ãã³ã¿ããããååã®çååŠçç¹æ§åã³å€©ç¶é
ç³æ§é ã®ä¿æããèœåã¯æ¬¡ã®äºå®ããæããã§ã
ããå³ã¡ãæ¬çºæã®ãã³ã¿ããããæ§é äœã¯ç±³åœ
ç¹èš±ç¬¬4002602å·ã«æŒããŠãŠãããã³
ïŒUbiquitinïŒãšããŠé瀺ããã倩ç¶ã®74âã¢ãã
é žãããããšåãçååŠç¹æ§ã瀺ããšããäºå®ã§
ããããã®é·éã®ããªããããã®ååã®å éšã«æŒ
ããŠäžèšç¹èš±ã«èšèŒãããŠããä»ã®ã¢ããé žãšçµ
åããŠãããšãã圢ã§ã¯ãããæ¬çºæã®ãã³ã¿ã
ããããåå®ããããšãã§ãããããããªããã
æ¬çºæã®ãã³ã¿ãããããšãŠãããã³ã®çååŠæŽ»
æ§ã¯åäžã§ãããã€æ«ç«¯ã¢ããé žã眮æãããŠã
ãã¢ããé žé¡åã³ããããéã¯åºæ¬åœ¢ãã³ã¿ãã
ããæ§é äœã®çååŠç¹æ§ã«åœ±é¿ãåãŒããªãæ ã«
æ¬çºæã®ãã³ã¿ããããã掻æ§éšäœã§ãããšãã
ããšãäžèšç¹èš±ã¯çŽæ¥ç«èšŒããŠããã®ã§ããã
ç³æ§é ã®ä¿æããèœåã¯æ¬¡ã®äºå®ããæããã§ã
ããå³ã¡ãæ¬çºæã®ãã³ã¿ããããæ§é äœã¯ç±³åœ
ç¹èš±ç¬¬4002602å·ã«æŒããŠãŠãããã³
ïŒUbiquitinïŒãšããŠé瀺ããã倩ç¶ã®74âã¢ãã
é žãããããšåãçååŠç¹æ§ã瀺ããšããäºå®ã§
ããããã®é·éã®ããªããããã®ååã®å éšã«æŒ
ããŠäžèšç¹èš±ã«èšèŒãããŠããä»ã®ã¢ããé žãšçµ
åããŠãããšãã圢ã§ã¯ãããæ¬çºæã®ãã³ã¿ã
ããããåå®ããããšãã§ãããããããªããã
æ¬çºæã®ãã³ã¿ãããããšãŠãããã³ã®çååŠæŽ»
æ§ã¯åäžã§ãããã€æ«ç«¯ã¢ããé žã眮æãããŠã
ãã¢ããé žé¡åã³ããããéã¯åºæ¬åœ¢ãã³ã¿ãã
ããæ§é äœã®çååŠç¹æ§ã«åœ±é¿ãåãŒããªãæ ã«
æ¬çºæã®ãã³ã¿ããããã掻æ§éšäœã§ãããšãã
ããšãäžèšç¹èš±ã¯çŽæ¥ç«èšŒããŠããã®ã§ããã
ãã®ããšãããåŒã®ïŒ²åã³Râ²ãšããŠã¯åºæ¬
圢掻æ§æ§é äœã®çååŠç掻æ§ã«å®è³ªäžåœ±é¿ãäžã
ãªãããããããªã眮æäœã§ã䜿çšã§ããããšã
ç解ãããã§ããããåã³Râ²ã¯äŸãã°äžèšçœ®
æåºã®ãããã§ããããšæšå®ãããã
圢掻æ§æ§é äœã®çååŠç掻æ§ã«å®è³ªäžåœ±é¿ãäžã
ãªãããããããªã眮æäœã§ã䜿çšã§ããããšã
ç解ãããã§ããããåã³Râ²ã¯äŸãã°äžèšçœ®
æåºã®ãããã§ããããšæšå®ãããã
 Râ²
æ°ŽçŽ OH
C1âC7ã¢ã«ãã« NH2
C5âC12ã¢ãªãŒã« NHR7
C6âC20ã¢ã«ã«ãªãŒã« ïŒR7ïŒ2
C6âC20ã¢ã«ã¢ã«ãã« OR7
C2âC7ã¢ã«ã«ãã€ã«
C1âC7ã¢ã«ã±ãã«
C1âC7ã¢ã«ããã«
ããã§ãR7ã¯C1âC7ã®ã¢ã«ãã«ãC2âC7ã®ã¢
ã«ã±ãã«ãC2âC7ã®ã¢ã«ããã«ãC6âC20ã®ã¢ãª
ãŒã«ïŒC6âC20ã®ã¢ã«ã«ãªãŒã«åã¯C6âC20ã®ã¢ã«
ã¢ã«ãã«ã瀺ãã
ã«ã±ãã«ãC2âC7ã®ã¢ã«ããã«ãC6âC20ã®ã¢ãª
ãŒã«ïŒC6âC20ã®ã¢ã«ã«ãªãŒã«åã¯C6âC20ã®ã¢ã«
ã¢ã«ãã«ã瀺ãã
åã³Râ²ã¯åäžæ§ã¢ããé
žåºåã¯ççŽ ååæ°
ïŒâ20ã®ããªããããéã®æ®åºã§ãã€ãŠãããã
ãããã®äŸãäžèšã«ç€ºãã
ïŒâ20ã®ããªããããéã®æ®åºã§ãã€ãŠãããã
ãããã®äŸãäžèšã«ç€ºãã
 Râ²
ASP GLU
SER SER
LEU THR
SERâASP LEU
LEUâSERâASP HIS
LEUâASP VAL
LEUâSER ARG
GLUâSER
GLUâTHR
GLUâSERâLEU
GLUâSERâTHR
GLUâSERâTHRâLEU
GLUâSERâTHRâLEUâHIS
GLUâSERâTHRâLEUâHISâ
LEU GLUâSERâTHRâLEUâHISâ
LEUâVAL GLUâSERâTHRâLEUâHISâ
LEUâVALâLEU GLUâSERâTHRâLEUâHISâ
LEUâVALâLEUâARG GLUâSERâTHRâLEUâHISâ
LEUâVALâLEUâARGâLEU GLUâSERâTHRâLEUâHISâ
LEUâVALâLEUâARGâLEUâ
ARG æ¬çºæã®ä»ã®åèäŸã«ããã°ãäžèšåŒãæãã
æ°èŠãªãã³ã¿ããããããåŸãããšãã§ããã
LEU GLUâSERâTHRâLEUâHISâ
LEUâVAL GLUâSERâTHRâLEUâHISâ
LEUâVALâLEU GLUâSERâTHRâLEUâHISâ
LEUâVALâLEUâARG GLUâSERâTHRâLEUâHISâ
LEUâVALâLEUâARGâLEU GLUâSERâTHRâLEUâHISâ
LEUâVALâLEUâARGâLEUâ
ARG æ¬çºæã®ä»ã®åèäŸã«ããã°ãäžèšåŒãæãã
æ°èŠãªãã³ã¿ããããããåŸãããšãã§ããã
äžåŒã§ãã¯æ°ŽçŽ ãã¡ãã«ããšãã«çã®C1â
C7ã®ã¢ã«ãã«ãããšãã«çã®C5âC12ã®ã¢ãªãŒ
ã«ãã¢ã»ãã«ãããããªãã«çã®C1âC7ã®ã¢ã«
ã«ãã€ã«ãRâ²ã¯OHïŒNH2ïŒNHR7åã¯ïŒ®ïŒR7ïŒ2
ã瀺ããæã奜ãŸããããªããããé¡ã¯ïŒ²ãæ°Ž
çŽ ãRâ²ãOHã§ããããããé¡ã§ããã
C7ã®ã¢ã«ãã«ãããšãã«çã®C5âC12ã®ã¢ãªãŒ
ã«ãã¢ã»ãã«ãããããªãã«çã®C1âC7ã®ã¢ã«
ã«ãã€ã«ãRâ²ã¯OHïŒNH2ïŒNHR7åã¯ïŒ®ïŒR7ïŒ2
ã瀺ããæã奜ãŸããããªããããé¡ã¯ïŒ²ãæ°Ž
çŽ ãRâ²ãOHã§ããããããé¡ã§ããã
ãã³ã¿ãããããšå¡©ã圢æãåŸãé
žãšããŠã¯å¡©
é žãèåæ°ŽçŽ é žãéå¡©çŽ é žãç¡é žãããªã·ã¢ã³
é žãç¡«é žãçé žçã®ç¡æ©é žãšè»é žãé ¢é žãããã
ãªã³é žãã°ãªã³ãŒã«é žãä¹³é žããã«ãã³é žãè
é žãããã³é žãã³ãã¯é žããã¬ã€ã³é žããããŒã«
é žãã¢ã³ãã©ãã«é žãæ¡ç®é žãããã¿ãªã³ã¹ã«ã
ã³é žãã¹ã«ãã¢ãã«é žçã®ææ©é žãšãæããããš
ãã§ããã
é žãèåæ°ŽçŽ é žãéå¡©çŽ é žãç¡é žãããªã·ã¢ã³
é žãç¡«é žãçé žçã®ç¡æ©é žãšè»é žãé ¢é žãããã
ãªã³é žãã°ãªã³ãŒã«é žãä¹³é žããã«ãã³é žãè
é žãããã³é žãã³ãã¯é žããã¬ã€ã³é žããããŒã«
é žãã¢ã³ãã©ãã«é žãæ¡ç®é žãããã¿ãªã³ã¹ã«ã
ã³é žãã¹ã«ãã¢ãã«é žçã®ææ©é žãšãæããããš
ãã§ããã
äžèšæ§é äœã«æŒããŠããããã®ã¢ããé
žæåã¯
䟿å®äžç¥å·ã§ç€ºãããããããã®ç¥å·ã¯äžèšã¢ã
ãé žã瀺ãã
䟿å®äžç¥å·ã§ç€ºãããããããã®ç¥å·ã¯äžèšã¢ã
ãé žã瀺ãã
ã¢ããé
ž ç¥å·
âããã·ã³ TYR
âã¢ã¹ãã©ã®ã³ ASN
âã¢ã¹ãã©ã®ã³ ASP
âã€ãœãã€ã·ã³ ILE
âã»ãªã³ SER
âã°ã«ã¿ãã³ GLN
âãã€ã·ã³ LEU
âãªã·ã³ LYS
âã°ã«ã¿ãã³é
ž GLU
âã¹ã¬ãªãã³ THR
âãã¹ããžã³ HIS
âããªã³ VAL
âã¢ã«ã®ãã³ ARG
âã¢ã©ãã³ ALA
æ¬çºæã®ããªããããé¡ã¯ïŒâã¢ããé
žããã
ãé¡ã§ããããã®ããããã¯ç±³åœç¹èš±ç¬¬4002602
å·ã«é瀺ãããŠããåŠãçã®èžç·ããåé¢ããã
74âã¢ããé žããªããããã§ãããŠãããã³
ïŒUBIPïŒã«äŒŒãç¹æ§ã瀺ãããšãåã€ããæ¬çº
æã®ããããé¡ã¯ããã°ã©ã åäœã®æ¿åºŠã§ïŒ¢å é§
äœçŽ°èãšåæã«ïŒŽå é§äœçŽ°èã®éžæçååãèªå°
ããããšãã§ããç¹ã«ãã®ç¹åŸŽããããæ¬çºæã®
ããªããããé¡ã¯ç±³åœç¹èš±ç¬¬4002602å·ã«é瀺ã
ããŠããé·éããªããããé¡ãšåæ§ã«è©Šéšç®¡äžã§
å ç«çŽ°èå é§äœçŽ°èãååãããããšãåã€ãã
å³ã¡ãæ¬çºæã®ããªããããé¡ã¯äŸãããã°ã©ã
åäœã®æ¿åºŠã§ãèžç·ååæåTLåã³THYâïŒ
ïŒÎžïŒã®ç²åŸã«ãã枬å®ããããããªïŒŽå é§äœçŽ°
èãšïŒ¢çŽ°èã®èå¥ããŒã«ãŒïŒmarkerïŒã§ããè£
äœå容äœã®ç²åŸã«ãã枬å®ããããããªïŒ¢å é§äœ
现èãšã®ååãèªå°ããããšãåã€ãã
ãé¡ã§ããããã®ããããã¯ç±³åœç¹èš±ç¬¬4002602
å·ã«é瀺ãããŠããåŠãçã®èžç·ããåé¢ããã
74âã¢ããé žããªããããã§ãããŠãããã³
ïŒUBIPïŒã«äŒŒãç¹æ§ã瀺ãããšãåã€ããæ¬çº
æã®ããããé¡ã¯ããã°ã©ã åäœã®æ¿åºŠã§ïŒ¢å é§
äœçŽ°èãšåæã«ïŒŽå é§äœçŽ°èã®éžæçååãèªå°
ããããšãã§ããç¹ã«ãã®ç¹åŸŽããããæ¬çºæã®
ããªããããé¡ã¯ç±³åœç¹èš±ç¬¬4002602å·ã«é瀺ã
ããŠããé·éããªããããé¡ãšåæ§ã«è©Šéšç®¡äžã§
å ç«çŽ°èå é§äœçŽ°èãååãããããšãåã€ãã
å³ã¡ãæ¬çºæã®ããªããããé¡ã¯äŸãããã°ã©ã
åäœã®æ¿åºŠã§ãèžç·ååæåTLåã³THYâïŒ
ïŒÎžïŒã®ç²åŸã«ãã枬å®ããããããªïŒŽå é§äœçŽ°
èãšïŒ¢çŽ°èã®èå¥ããŒã«ãŒïŒmarkerïŒã§ããè£
äœå容äœã®ç²åŸã«ãã枬å®ããããããªïŒ¢å é§äœ
现èãšã®ååãèªå°ããããšãåã€ãã
æ¬çºæã®ããªããããé¡ã®çååŠçååç¹æ§ã®
éèŠæ§ãç解ããã«ã¯ãå ç«ã«é¢ããèžç·ã®æ©èœ
ã¯åºçŸ©ã«èšãã°ïŒŽçŽ°èãšèšãããèžç·ã«ç±æ¥ãã
现èå³ã¡ãªã³ãçãçæããããšã§ãããšããã
ãšãã§ããããšãéèšãã¹ãã§ããã现èã¯å
埪ç°å°ãªã³ãç貯槜ã®å€§éšåã圢æããŠããã
现èã¯å ç«åŠçç¹ç°æ§ãæããã€å®è¡åšçŽ°èãšã
ãŠïŒå皮移æ€åå¿çã®ïŒçŽ°èä»åšã«ããå ç«å¿ç
ã«çŽæ¥é¢äžããŠãããããããªããã现èã¯æ¶²
æ§æäœãåæ³ããããšã¯ãªãããããã®æäœã¯èž
ç·ãšã¯ç¡é¢ä¿ã«éªšé«ã«çŽæ¥ç±æ¥ãã现èã«ããå
æ³ãããããããã®éªšé«ã«ç±æ¥ãã现èã¯ïŒ¢çŽ°è
ãšèšããããããããªãããå€ãã®æåãšã¯å¯Ÿç§°
çã«ã现èãæäœãçæããã«ã¯é©åœã«åå¿æ§
ã®ãã现èã®ååšãå¿ èŠã§ããã现èãšïŒ¢çŽ°
èã®ååã«ãããã®çæéçšã®æ©æ§ã¯æªã å®å šã«
ã¯ç解ãããŠããªãã
éèŠæ§ãç解ããã«ã¯ãå ç«ã«é¢ããèžç·ã®æ©èœ
ã¯åºçŸ©ã«èšãã°ïŒŽçŽ°èãšèšãããèžç·ã«ç±æ¥ãã
现èå³ã¡ãªã³ãçãçæããããšã§ãããšããã
ãšãã§ããããšãéèšãã¹ãã§ããã现èã¯å
埪ç°å°ãªã³ãç貯槜ã®å€§éšåã圢æããŠããã
现èã¯å ç«åŠçç¹ç°æ§ãæããã€å®è¡åšçŽ°èãšã
ãŠïŒå皮移æ€åå¿çã®ïŒçŽ°èä»åšã«ããå ç«å¿ç
ã«çŽæ¥é¢äžããŠãããããããªããã现èã¯æ¶²
æ§æäœãåæ³ããããšã¯ãªãããããã®æäœã¯èž
ç·ãšã¯ç¡é¢ä¿ã«éªšé«ã«çŽæ¥ç±æ¥ãã现èã«ããå
æ³ãããããããã®éªšé«ã«ç±æ¥ãã现èã¯ïŒ¢çŽ°è
ãšèšããããããããªãããå€ãã®æåãšã¯å¯Ÿç§°
çã«ã现èãæäœãçæããã«ã¯é©åœã«åå¿æ§
ã®ãã现èã®ååšãå¿ èŠã§ããã现èãšïŒ¢çŽ°
èã®ååã«ãããã®çæéçšã®æ©æ§ã¯æªã å®å šã«
ã¯ç解ãããŠããªãã
äžè¿°ã®ããšãããäœçšå¹æãšãã芳ç¹ã«æŒããŠ
èžç·ã¯çŽ°èå ç«ã®çºçŸåã³å€ãã®æ¶²æ§æäœåå¿ã«
察ããŠå¿ èŠãªãã®ã§ãããã€é è¡æ§å¹¹çŽ°èãåå
ããŠïŒŽçŽ°èãèžç·å ã§èªå°ããããšã«ããäžèšçº
çŸåã³åå¿ç³»ã«èžç·ã¯åœ±é¿ãäžããŠãããšããã
ãšãã§ããããã®èªå°ç圱é¿ã¯èžç·ã®äžç®çŽ°èã®
åæ³ç©ãå³ã¡èžç·ãã«ã¢ã³é¡ãåªä»ãšããŠè¡ãã
ãã
èžç·ã¯çŽ°èå ç«ã®çºçŸåã³å€ãã®æ¶²æ§æäœåå¿ã«
察ããŠå¿ èŠãªãã®ã§ãããã€é è¡æ§å¹¹çŽ°èãåå
ããŠïŒŽçŽ°èãèžç·å ã§èªå°ããããšã«ããäžèšçº
çŸåã³åå¿ç³»ã«èžç·ã¯åœ±é¿ãäžããŠãããšããã
ãšãã§ããããã®èªå°ç圱é¿ã¯èžç·ã®äžç®çŽ°èã®
åæ³ç©ãå³ã¡èžç·ãã«ã¢ã³é¡ãåªä»ãšããŠè¡ãã
ãã
æŽã«ãèžç·åã³ãªã³ãç现èç³»ã®äœçšåã³äœå
ã§ã®ãªã³ãçã®åŸªç°ãç解ããã«ã¯ã幹现èã¯éªš
é«ã«çããŠè¡æ¶²ã«éã°ããŠèžç·ã«éãããšããã
ãšãæããŠããå¿ èŠããããèžç·ã®å éšã«æŒã
ãŠã幹现èã¯å ç«åŠçã«æèœãªïŒŽçŽ°èã«ååãã
现èã¯è¡æµã«ç§»è¡ã现èãšå ±ã«çš®ã ã®çµç¹ã
ãªã³ã管系ã³è¡æµéã埪ç°ããã
ã§ã®ãªã³ãçã®åŸªç°ãç解ããã«ã¯ã幹现èã¯éªš
é«ã«çããŠè¡æ¶²ã«éã°ããŠèžç·ã«éãããšããã
ãšãæããŠããå¿ èŠããããèžç·ã®å éšã«æŒã
ãŠã幹现èã¯å ç«åŠçã«æèœãªïŒŽçŽ°èã«ååãã
现èã¯è¡æµã«ç§»è¡ã现èãšå ±ã«çš®ã ã®çµç¹ã
ãªã³ã管系ã³è¡æµéã埪ç°ããã
æäœãåæ³ãã身äœçŽ°èãåé è¡å¹¹çŽ°èããçº
çãããã®ã§ããã身äœçŽ°èã®ååã¯èžç·ã«ãã
決ãŸããã®ã§ã¯ãªããåŸã€ãŠã身äœçŽ°èã¯éªšé«ç±
æ¥çŽ°èå³ã¡ïŒ¢çŽ°èãšåä»ããããŠãããé³¥é¡ã«æŒ
ããŠã¯ã身äœçŽ°èã¯èžç·ã«é¡äŒŒãããã¢ããªããŠ
ã¹å¢ãšããåšå®ã§ååããããåºä¹³é¡ã§ã¯ããã¢
ããªããŠã¹å¢ã«çžåœããåšå®ã¯èŠåºãããŠããã
现èã¯éªšé«å ã§ååãããšèããããŠãããã
ã®ååãè¡ãããçççç©è³ªã¯å šãåã€ãŠããª
ãã
çãããã®ã§ããã身äœçŽ°èã®ååã¯èžç·ã«ãã
決ãŸããã®ã§ã¯ãªããåŸã€ãŠã身äœçŽ°èã¯éªšé«ç±
æ¥çŽ°èå³ã¡ïŒ¢çŽ°èãšåä»ããããŠãããé³¥é¡ã«æŒ
ããŠã¯ã身äœçŽ°èã¯èžç·ã«é¡äŒŒãããã¢ããªããŠ
ã¹å¢ãšããåšå®ã§ååããããåºä¹³é¡ã§ã¯ããã¢
ããªããŠã¹å¢ã«çžåœããåšå®ã¯èŠåºãããŠããã
现èã¯éªšé«å ã§ååãããšèããããŠãããã
ã®ååãè¡ãããçççç©è³ªã¯å šãåã€ãŠããª
ãã
äžè¿°ã®åŠããæ¬çºæã®ããªããããé¡ã¯äººéå
ã³åç©ã®æ²»çã«æå¹ã§ãããæ¬çºæã®ããªããã
ãé¡ã¯é è¡çµç¹ããçããé ãªã³ãç幹现èãå
åããŠèº«äœã®å ç«å¿çã«é¢äžããããšãã§ããèž
ç·ç±æ¥çŽ°èå³ã¡ïŒŽçŽ°èã«èªå°ããããšãã§ããã€
现èã®ååããèªå°ã§ããã®ã§ãããªãããã
é¡ã¯å€ãã®æ²»çäžã®çšéãæãããã®ã§ãããšæ
ãããã第ïŒã«ãæ¬çºæã®ããªããããååç©ã¯
èžç·ã®æ©èœã®å æãçš®ã®æ©èœãéè¡ã§ããã®ã§
çš®ã ã®èžç·æ©èœåéåã³å ç«åéã«é©çšã§ããã
çšéã®äž»åéã¯å 倩æ§èžç·æ¬ åŠã®ç¶æ ã§ãããã€
ãžãšãŒãžïŒDi DeorgeïŒçå矀ã®æ²»çã§ãããæ¬
çºæã®ããªããããé¡ã®æ³šå ¥ã«ãããã®æ¬ é¥åã¯
æ¬ å€±ã«æåã€ããšãã§ãããä»ã®é©çšäŸãšããŠã¯
身äœã®ïŒ¢çŽ°èååæ§æšå®ãã«ã¢ã³ã®æ¬ åŠã«äŸãç¡
ã¬ã³ãã°ãããªã³è¡çã®æ²»çã§ããããããããª
ããããé¡ã®æ³šå ¥ã«ããæ²»çããããšãã§ããã
äœæ¿åºŠã§çšããŠãéåžžã«æŽ»æ§ãããããªãããã
é¡ã®çååŠçç¹æ§ã®æ ã«ãããªããããé¡ã¯çŽ°è
å ç«åã³æ¶²æ§å ç«ã®æ²»ççåºæ¿ãå¢å€§åã¯ä¿é²
ããåŸã€ãŠçŽ°èæ§åã¯ãã€ã³ãã©ãºãäŒæç ãçµ
æ žãç©ç ãæ¥æ§åã³æ ¢æ§ããŒã«ã¹æ§äŒæç çã®ç
ç©äœäžã«ããæ ¢æ§äŒææ§ç æ°ã®æ²»çã«æå¹ã§ãã
身äœã®ç·åçå ç«ãå©æãããšããç¹ã«æŒããŠæ
å¹ã§ãããæŽã«ãããªããããååç©ã¯çŽ°èåã¯
液æ§å ç«ãåé¡ã§ããåéãç¹ã«åè¿°ãã€ãžãšãŒ
ãžçå矀ã«æŒããåŠãå ç«ã«æ¬ æãããåéã«æ
å¹ã§ãããšæããããåãããªããããé¡ã®åè¿°
ç¹æ§ã®æ ã«ãããªããããé¡ã¯è©Šéšç®¡äžã§ã®ïŒŽçŽ°
èã®è¡šé¢æåã®çºè²ã«æå¹ã§ãããæ©èœçèœåã
çºçŸãããŠçŽ°èåè£ç©è³ªåã³æåã«å¿çãããã
ãšã«æå¹ã§ããããã€çŽ°èãååãããŠïŒ¢çŽ°èã®
èœåãé«ããŠçš®ã ã®æäœãçæãããããšãã§ã
ããæŽã«ãããªããããé¡ã¯è£äœã®è¡šé¢å容äœã®
çºè²ã«ãã枬å®ãããåŠã现èãè©Šéšç®¡äžã§çº
è²ãããããšãã§ãããæ¬çºæã®ããªããããé¡
ã¯åãŠãããã³å¿çæ§ãªã³ãçã®ç¡å¶éã®å¢æ€ã
çŠæ¢ããã«ãæå¹ã§ããã
ã³åç©ã®æ²»çã«æå¹ã§ãããæ¬çºæã®ããªããã
ãé¡ã¯é è¡çµç¹ããçããé ãªã³ãç幹现èãå
åããŠèº«äœã®å ç«å¿çã«é¢äžããããšãã§ããèž
ç·ç±æ¥çŽ°èå³ã¡ïŒŽçŽ°èã«èªå°ããããšãã§ããã€
现èã®ååããèªå°ã§ããã®ã§ãããªãããã
é¡ã¯å€ãã®æ²»çäžã®çšéãæãããã®ã§ãããšæ
ãããã第ïŒã«ãæ¬çºæã®ããªããããååç©ã¯
èžç·ã®æ©èœã®å æãçš®ã®æ©èœãéè¡ã§ããã®ã§
çš®ã ã®èžç·æ©èœåéåã³å ç«åéã«é©çšã§ããã
çšéã®äž»åéã¯å 倩æ§èžç·æ¬ åŠã®ç¶æ ã§ãããã€
ãžãšãŒãžïŒDi DeorgeïŒçå矀ã®æ²»çã§ãããæ¬
çºæã®ããªããããé¡ã®æ³šå ¥ã«ãããã®æ¬ é¥åã¯
æ¬ å€±ã«æåã€ããšãã§ãããä»ã®é©çšäŸãšããŠã¯
身äœã®ïŒ¢çŽ°èååæ§æšå®ãã«ã¢ã³ã®æ¬ åŠã«äŸãç¡
ã¬ã³ãã°ãããªã³è¡çã®æ²»çã§ããããããããª
ããããé¡ã®æ³šå ¥ã«ããæ²»çããããšãã§ããã
äœæ¿åºŠã§çšããŠãéåžžã«æŽ»æ§ãããããªãããã
é¡ã®çååŠçç¹æ§ã®æ ã«ãããªããããé¡ã¯çŽ°è
å ç«åã³æ¶²æ§å ç«ã®æ²»ççåºæ¿ãå¢å€§åã¯ä¿é²
ããåŸã€ãŠçŽ°èæ§åã¯ãã€ã³ãã©ãºãäŒæç ãçµ
æ žãç©ç ãæ¥æ§åã³æ ¢æ§ããŒã«ã¹æ§äŒæç çã®ç
ç©äœäžã«ããæ ¢æ§äŒææ§ç æ°ã®æ²»çã«æå¹ã§ãã
身äœã®ç·åçå ç«ãå©æãããšããç¹ã«æŒããŠæ
å¹ã§ãããæŽã«ãããªããããååç©ã¯çŽ°èåã¯
液æ§å ç«ãåé¡ã§ããåéãç¹ã«åè¿°ãã€ãžãšãŒ
ãžçå矀ã«æŒããåŠãå ç«ã«æ¬ æãããåéã«æ
å¹ã§ãããšæããããåãããªããããé¡ã®åè¿°
ç¹æ§ã®æ ã«ãããªããããé¡ã¯è©Šéšç®¡äžã§ã®ïŒŽçŽ°
èã®è¡šé¢æåã®çºè²ã«æå¹ã§ãããæ©èœçèœåã
çºçŸãããŠçŽ°èåè£ç©è³ªåã³æåã«å¿çãããã
ãšã«æå¹ã§ããããã€çŽ°èãååãããŠïŒ¢çŽ°èã®
èœåãé«ããŠçš®ã ã®æäœãçæãããããšãã§ã
ããæŽã«ãããªããããé¡ã¯è£äœã®è¡šé¢å容äœã®
çºè²ã«ãã枬å®ãããåŠã现èãè©Šéšç®¡äžã§çº
è²ãããããšãã§ãããæ¬çºæã®ããªããããé¡
ã¯åãŠãããã³å¿çæ§ãªã³ãçã®ç¡å¶éã®å¢æ€ã
çŠæ¢ããã«ãæå¹ã§ããã
现èã®ç¹æ§ãçšããŠçŽ°èãå埩ãããããšã
ã§ãããšããçç©äœäžã§ã®æ§è³ªå现èã®ç¹æ§ã
çšããŠçŽ°èãå埩ãããããšãã§ãããšããçç©
äœäžã§ã®ããªããããã®æ§è³ªãããªããããã®é
èŠãªç¹æ§ã®ïŒã€ã§ããã
ã§ãããšããçç©äœäžã§ã®æ§è³ªå现èã®ç¹æ§ã
çšããŠçŽ°èãå埩ãããããšãã§ãããšããçç©
äœäžã§ã®ããªããããã®æ§è³ªãããªããããã®é
èŠãªç¹æ§ã®ïŒã€ã§ããã
æ¬çºæã®ããªããããé¡ã®æŽã«éèŠãªæ§è³ªã¯ã
ãªããããé¡ã¯éåžžã«äœæ¿åºŠã§éåžžã«æŽ»æ§ã§ãã
ãšããããšã§ãããå³ã¡ãããªããããé¡ã¯10n
ïœïŒml以äžã®æ¿åºŠã§æŽ»æ§ã§ãããçŽ0.05â1ÎŒïœïŒ
mlã®æ¿åºŠã§æŽ»æ§ã¯æ倧ãšãªãããã®ããªãããã
ã®æ äœãšããŠã¯ãã®æ§ãªç®çã«å¯ŸããŠéåžžçšãã
ããå ¬ç¥ã®æ äœã¯ãããã䜿çšå¯èœã§ãããäŸã
ã°éåžžã®å¡©æ°Žæº¶æ¶²ã䜿çšã§ããããã®å Žåçã®è¡
æž ã¢ã«ããã³çã®ã¿ã³ãã¯è³ªåžéå€ãå«ãŸããŠäž
èšäœæ¿åºŠã§çšããããããªãããããã¬ã©ã¹åšå ·
ã«åžçæ倱ããããšã®ãªãããã«ããããšã奜ãŸ
ãããæ¬çºæã®ããªããããé¡ã¯äœéïŒKgã«å¯Ÿã
ãŠçŽ0.1mg以äžã®ç¯å²ã§æŽ»æ§ã§ããããã€ãžãšãŒ
ãžç䟯矀ã®æ²»çã«ã¯ãããªããããé¡ã¯äœéïŒKg
åœãçŽ1.0â10mgæäžããã°ãããäžè¬ã«ã¯ãäž
èšæäžéã¯ãããŸã§æããä»ã®çç¶åã¯ç æ°ã®åŠ
眮ã«å¯ŸããŠãæå¹ã§ããã
ãªããããé¡ã¯éåžžã«äœæ¿åºŠã§éåžžã«æŽ»æ§ã§ãã
ãšããããšã§ãããå³ã¡ãããªããããé¡ã¯10n
ïœïŒml以äžã®æ¿åºŠã§æŽ»æ§ã§ãããçŽ0.05â1ÎŒïœïŒ
mlã®æ¿åºŠã§æŽ»æ§ã¯æ倧ãšãªãããã®ããªãããã
ã®æ äœãšããŠã¯ãã®æ§ãªç®çã«å¯ŸããŠéåžžçšãã
ããå ¬ç¥ã®æ äœã¯ãããã䜿çšå¯èœã§ãããäŸã
ã°éåžžã®å¡©æ°Žæº¶æ¶²ã䜿çšã§ããããã®å Žåçã®è¡
æž ã¢ã«ããã³çã®ã¿ã³ãã¯è³ªåžéå€ãå«ãŸããŠäž
èšäœæ¿åºŠã§çšããããããªãããããã¬ã©ã¹åšå ·
ã«åžçæ倱ããããšã®ãªãããã«ããããšã奜ãŸ
ãããæ¬çºæã®ããªããããé¡ã¯äœéïŒKgã«å¯Ÿã
ãŠçŽ0.1mg以äžã®ç¯å²ã§æŽ»æ§ã§ããããã€ãžãšãŒ
ãžç䟯矀ã®æ²»çã«ã¯ãããªããããé¡ã¯äœéïŒKg
åœãçŽ1.0â10mgæäžããã°ãããäžè¬ã«ã¯ãäž
èšæäžéã¯ãããŸã§æããä»ã®çç¶åã¯ç æ°ã®åŠ
眮ã«å¯ŸããŠãæå¹ã§ããã
æ¬çºæã®ããªããããé¡ã¯ãJournal Of
American Chemical Societyã85ïŒp.2149â
2154ïŒ1963ãã«èšèŒãããŠãããããªã¡ãªãã€ãŒ
ã«ãã®æŠå¿µãšåæ§ã®æŠå¿µãçšããŠè£œé ããããå³
ã¡ãæ°çš®ã®ä¿è·åœ¢ã¢ããé žã段éçã«åºåœ¢æš¹èç²
ã«å ±æçµåã§çµåãããŠããçé·ããããéã«ä»
å ããããšã«ããåæãè¡ã€ãããã®æ¹æ³ã§ã¯ã
è¬å€åã³å¯çç©ã¯æ¿Ÿéåã³äžéäœã®åçµæ¶ã«ãã
é€å»ãããããã®æ¹æ³ãäžè¬çã«èšãã°ãããã
ãéã®ç¬¬ïŒã®ã¢ããé žãåºäœé«ååã«å ±æçµåã§
çµåãããåŒç¶ãã¢ããé žãäžåºŠã«ïŒçš®é¡ã¥ã€é
段çã«ä»å ããŠææã®æ§é åäœãæ§æããæ¹æ³ã§
ãããæåŸã«ããããããåºåœ¢æ¯æäœããåé¢ã
ãã€ä¿è·åºãé€ãããã®æ¹æ³ã«ããã°çé·ããã
ãããéã¯å®å šã«äžæº¶æ§ã®åºäœç²åã«çµåããŠã
ãã®ã§æ¿ŸéæŽæµããŠè¬å€åã³å¯çç©ãé€ãã«ã¯éœ
åãããã
American Chemical Societyã85ïŒp.2149â
2154ïŒ1963ãã«èšèŒãããŠãããããªã¡ãªãã€ãŒ
ã«ãã®æŠå¿µãšåæ§ã®æŠå¿µãçšããŠè£œé ããããå³
ã¡ãæ°çš®ã®ä¿è·åœ¢ã¢ããé žã段éçã«åºåœ¢æš¹èç²
ã«å ±æçµåã§çµåãããŠããçé·ããããéã«ä»
å ããããšã«ããåæãè¡ã€ãããã®æ¹æ³ã§ã¯ã
è¬å€åã³å¯çç©ã¯æ¿Ÿéåã³äžéäœã®åçµæ¶ã«ãã
é€å»ãããããã®æ¹æ³ãäžè¬çã«èšãã°ãããã
ãéã®ç¬¬ïŒã®ã¢ããé žãåºäœé«ååã«å ±æçµåã§
çµåãããåŒç¶ãã¢ããé žãäžåºŠã«ïŒçš®é¡ã¥ã€é
段çã«ä»å ããŠææã®æ§é åäœãæ§æããæ¹æ³ã§
ãããæåŸã«ããããããåºåœ¢æ¯æäœããåé¢ã
ãã€ä¿è·åºãé€ãããã®æ¹æ³ã«ããã°çé·ããã
ãããéã¯å®å šã«äžæº¶æ§ã®åºäœç²åã«çµåããŠã
ãã®ã§æ¿ŸéæŽæµããŠè¬å€åã³å¯çç©ãé€ãã«ã¯éœ
åãããã
ã¢ããé
žé¡ã¯é©åœãªããªããŒã«çµåãããããš
ãã§ããããã®å ŽååèšããªããŒã¯äœ¿çšæº¶åªã«äž
溶æ§ã§ãªããã°ãªããåæ¿Ÿéã容æã«è¡ãããã
ãšãã§ããç©ççã«å®å®ãªåœ¢ç¶ã§ãªããã°ãªããª
ããåãããªããŒã¯ç¬¬ïŒã®ä¿è·åœ¢ã¢ããé žãå ±æ
çµåã§ç¢ºå®ã«çµåã§ããå®èœåºãå«ããã®ã§ãªã
ãã°ãªããªããçš®ã ã®ããªããŒã䜿çšå¯èœã§ãã
äŸãã°ã»ã«ããŒãºãããªããã«ã¢ã«ã³ãŒã«ãããª
ã¡ã¿ã¢ã¯ã¬ãŒããã¹ã«ãã³åããªã¹ãã¬ã³ãæã
ãããšãã§ããããæ¬çºæã§è¡ã€ãåæã§ã¯ã¹ã
ã¬ã³åã³ãžããã«ãã³ãŒã³ã®ã¯ãã«ã¡ãã«åäŸé
åäœãçšããããã
ãã§ããããã®å ŽååèšããªããŒã¯äœ¿çšæº¶åªã«äž
溶æ§ã§ãªããã°ãªããåæ¿Ÿéã容æã«è¡ãããã
ãšãã§ããç©ççã«å®å®ãªåœ¢ç¶ã§ãªããã°ãªããª
ããåãããªããŒã¯ç¬¬ïŒã®ä¿è·åœ¢ã¢ããé žãå ±æ
çµåã§ç¢ºå®ã«çµåã§ããå®èœåºãå«ããã®ã§ãªã
ãã°ãªããªããçš®ã ã®ããªããŒã䜿çšå¯èœã§ãã
äŸãã°ã»ã«ããŒãºãããªããã«ã¢ã«ã³ãŒã«ãããª
ã¡ã¿ã¢ã¯ã¬ãŒããã¹ã«ãã³åããªã¹ãã¬ã³ãæã
ãããšãã§ããããæ¬çºæã§è¡ã€ãåæã§ã¯ã¹ã
ã¬ã³åã³ãžããã«ãã³ãŒã³ã®ã¯ãã«ã¡ãã«åäŸé
åäœãçšããããã
掻æ§ã§ã¯ãããåå¿ã«ã¯é¢äžãã¹ãã§ãªãã¢ã
ãé žã®åçš®å®èœåºã¯ããªããããã®å Žåé垞䜿çš
ãããå ¬ç¥ã®ä¿è·åºã«ããåæåå¿ã®éäžä¿è·ã
ãŠããããããã·ã³åã³ãªã·ã³ã®å®èœåºã¯ãæçµ
ããªããããçæç©ã«æªåœ±é¿ãäžããã«æ®µéçä»
å åå¿ã®å®äºæã«é€ãããšãã§ããä¿è·åºã«ãã
ä¿è·ããããã«ãããªã³ã°ãå®äºãããã©ããã
éœæ§èå ã®æ瀺ã«ãã決ããããã«ãã«ãªã¬ã¹ã¢
ãã³ïŒFluorescamineïŒã䜿çšãããšããç¹
ïŒFelix et alã«ããAnalyt.Biochem.ïŒ52ïŒ377ïŒ
1973åç §ïŒã«æŒããŠããªããããã®åæã¯åºäœå
ææ³ã®æ¹è¯æ³ã«ããè¡ããããã«ãããªã³ã°ã®å®
äºãæ瀺ãããªãå Žåã«ã¯ãαâã¢ããä¿è·è§£é€
ãè¡ãåã«åäžã®ä¿è·åœ¢ã¢ããé žãçšããŠã«ãã
ãªã³ã°ãç¹°è¿ããã
ãé žã®åçš®å®èœåºã¯ããªããããã®å Žåé垞䜿çš
ãããå ¬ç¥ã®ä¿è·åºã«ããåæåå¿ã®éäžä¿è·ã
ãŠããããããã·ã³åã³ãªã·ã³ã®å®èœåºã¯ãæçµ
ããªããããçæç©ã«æªåœ±é¿ãäžããã«æ®µéçä»
å åå¿ã®å®äºæã«é€ãããšãã§ããä¿è·åºã«ãã
ä¿è·ããããã«ãããªã³ã°ãå®äºãããã©ããã
éœæ§èå ã®æ瀺ã«ãã決ããããã«ãã«ãªã¬ã¹ã¢
ãã³ïŒFluorescamineïŒã䜿çšãããšããç¹
ïŒFelix et alã«ããAnalyt.Biochem.ïŒ52ïŒ377ïŒ
1973åç §ïŒã«æŒããŠããªããããã®åæã¯åºäœå
ææ³ã®æ¹è¯æ³ã«ããè¡ããããã«ãããªã³ã°ã®å®
äºãæ瀺ãããªãå Žåã«ã¯ãαâã¢ããä¿è·è§£é€
ãè¡ãåã«åäžã®ä¿è·åœ¢ã¢ããé žãçšããŠã«ãã
ãªã³ã°ãç¹°è¿ããã
åæã®äžè¬çæ¹æ³ãšããŠã¯å
ã¥ã¢ããåºãä¿è·
ãããâãªã·ã³ãã¢ãã³ãå«ãç¡æ°Žã¢ã«ã³ãŒã«
äžã§æš¹èã«å¯ŸããŠãšã¹ãã«åãããçµåããã¢ã
ãé žæš¹èãæ¿Ÿéããã¢ã«ã³ãŒã«ã次ãã§æ°Žã§æŽæµ
ãã也ç¥ããã次ãã§ãªã·ã³ã¢ããé žã®Î±âã¢ã
ãåºã®ä¿è·åºïŒäŸãã°ïœâBOCãå³ã¡ïœâãã
ã«ãªãã·ã«ã«ããã«ïŒãä»ã®ä¿è·åºã«åœ±é¿ãäžã
ãããšãªãé€å»ãããéé¢ã¢ããåºãæããçµå
ã¢ããé žæš¹èãä¿è·åœ¢ïŒ¬âã°ã«ã¿ãã³é žã奜ãŸã
ãã¯ã¢ã«ãã¢âïœâBOCââã°ã«ã¿ãã³ããš
åå¿ãããŠïŒ¬âã°ã«ã¿ãã³ãçµåããããæŽã«ã
ä¿è·åœ¢ïŒ¬âã€ãœãã€ã·ã³ïŒïŒ¬âã¢ã¹ãã©ã®ã³åã³
âããã·ã³ãçšããŠåå¿ãç¹°è¿ãå®å šãªååã
åæãããäžèšåå¿ã¯äžèšã®åŠãè¡ã€ãã
ãããâãªã·ã³ãã¢ãã³ãå«ãç¡æ°Žã¢ã«ã³ãŒã«
äžã§æš¹èã«å¯ŸããŠãšã¹ãã«åãããçµåããã¢ã
ãé žæš¹èãæ¿Ÿéããã¢ã«ã³ãŒã«ã次ãã§æ°Žã§æŽæµ
ãã也ç¥ããã次ãã§ãªã·ã³ã¢ããé žã®Î±âã¢ã
ãåºã®ä¿è·åºïŒäŸãã°ïœâBOCãå³ã¡ïœâãã
ã«ãªãã·ã«ã«ããã«ïŒãä»ã®ä¿è·åºã«åœ±é¿ãäžã
ãããšãªãé€å»ãããéé¢ã¢ããåºãæããçµå
ã¢ããé žæš¹èãä¿è·åœ¢ïŒ¬âã°ã«ã¿ãã³é žã奜ãŸã
ãã¯ã¢ã«ãã¢âïœâBOCââã°ã«ã¿ãã³ããš
åå¿ãããŠïŒ¬âã°ã«ã¿ãã³ãçµåããããæŽã«ã
ä¿è·åœ¢ïŒ¬âã€ãœãã€ã·ã³ïŒïŒ¬âã¢ã¹ãã©ã®ã³åã³
âããã·ã³ãçšããŠåå¿ãç¹°è¿ãå®å šãªååã
åæãããäžèšåå¿ã¯äžèšã®åŠãè¡ã€ãã
æš¹è
â αâBOCâLysâCOOH
αâBOCâLysâæš¹è
â αâã¢ããä¿è·åºãé€ã
H2NâLysâæš¹è
â αâBOCââGln
αâBOCâGlnâLysâæš¹è
â αâã¢ããä¿è·åºãé€ã
H2NâGlnâLysâæš¹è
â αâBOCâIleâCOOH
αâBOCâIleâGlnâLysâæš¹è
â αâã¢ããä¿è·åºãé€ã
H2NâIleâGlnâæš¹èã¯
â αâBOCâAsnâCOOH
αâBOCâAsnâIleâGlnâLysâæš¹è
â αâã¢ããä¿è·åºãé€ã
H2NâAsnâIleâGlnâIysâæš¹è
â αâR3âTyrâCOOH
αâR3âTyrâAsnâIleâGlnâLysâæš¹è
â å
šãŠã®ä¿è·åºãé€ã
H2NâTyrâAsnâIleâGlnâLysâCOOH
äžèšäžé£ã®åå¿ã«æŒããŠãR1åã³R2ã¯åã¢ã
ãé žã®åå¿æ§åŽéã®ä¿è·åºã§ããããããã®ä¿è·
åºã¯Î±âã¢ããåºã®ä¿è·åºãé€ããŠæ¬¡ã®åå¿ãè¡
ãæäœã圱é¿ãåãããé€ããããããªããåα
âR3ã¯Î±âã¢ããåºã®ä¿è·åºã§ãããäžèšäžé
äœãã³ã¿ããããæš¹èã®å ŽåãR1ã¯ïŒ¯âïŒïŒïŒ
âãžã¯ãã«ãã³ãžã«çã®ä¿è·åºãR2ã¯ÎµâïŒâ
ã¯ãã«ãã³ãžã«ãªãã·ã«ã«ããã«ãR3ã¯ïœâã
ãã«ãªãã·ã«ã«ããã«ã§ããããšã奜ãŸãããæš¹
èã¯æ¬çºæã®æ¹æ³ã«æå¹ã§ãããã®ã§ããã°åè¿°
æš¹èã®ãããã§ããããäžèšäžé£ã®åå¿ã«æŒã
ãŠãALAïŒãTYRïŒASNåã¯ILEãšä»£ããŠåå¿
ãè¡ã€ãŠãåæ§ã«ããããé¡ãåæã§ããã
ãé žã®åå¿æ§åŽéã®ä¿è·åºã§ããããããã®ä¿è·
åºã¯Î±âã¢ããåºã®ä¿è·åºãé€ããŠæ¬¡ã®åå¿ãè¡
ãæäœã圱é¿ãåãããé€ããããããªããåα
âR3ã¯Î±âã¢ããåºã®ä¿è·åºã§ãããäžèšäžé
äœãã³ã¿ããããæš¹èã®å ŽåãR1ã¯ïŒ¯âïŒïŒïŒ
âãžã¯ãã«ãã³ãžã«çã®ä¿è·åºãR2ã¯ÎµâïŒâ
ã¯ãã«ãã³ãžã«ãªãã·ã«ã«ããã«ãR3ã¯ïœâã
ãã«ãªãã·ã«ã«ããã«ã§ããããšã奜ãŸãããæš¹
èã¯æ¬çºæã®æ¹æ³ã«æå¹ã§ãããã®ã§ããã°åè¿°
æš¹èã®ãããã§ããããäžèšäžé£ã®åå¿ã«æŒã
ãŠãALAïŒãTYRïŒASNåã¯ILEãšä»£ããŠåå¿
ãè¡ã€ãŠãåæ§ã«ããããé¡ãåæã§ããã
æçµäžéäœãåŸãããåŸãããããâæš¹èãå
å²ããŠR1ïŒR2åã³R3ä¿è·åºãšæš¹èãé€ããä¿è·
åºã¯ç¡æ°Žããåæ°ŽçŽ ã§åŠçããçã®éåžžã®æ段ã§
è¡ãããã®çµæåŸãããéé¢ãããããååã
ãã
å²ããŠR1ïŒR2åã³R3ä¿è·åºãšæš¹èãé€ããä¿è·
åºã¯ç¡æ°Žããåæ°ŽçŽ ã§åŠçããçã®éåžžã®æ段ã§
è¡ãããã®çµæåŸãããéé¢ãããããååã
ãã
æ¬çºæã®ããªããããé¡ã補é ããã«ã¯ãã¡ãª
ãã€ãŒã«ãæ³ã«æŒããåŠãäžæº¶æ§ããªããŒãå©çš
ããããšã奜ãŸããããå¿è«ä»ã®æ¹æ³ã§è£œé ãã
ããšãåºæ¥ããäŸãã°ãâã¡ãã«âãã³ãºãã
ãªã«ã¢ãã³æš¹èãããã¯ãã³ãºãããªã«ã¢ãã³æš¹
èçã®å¥ã®åºäœæ¯æäœã䜿çšããããšãã§ããã
ããã®æš¹èã䜿çšããããšãæå©ãªå Žåãããã
ãããã®æš¹èãçšããå Žåã«ã¯ãâæ«ç«¯ã¢ãã
é žãçŽæ¥æš¹èã«ä»çãããåŸãããããããã¯
HFäžã§æš¹èåºäœããåé¢ãããŠïŒ£âæ«ç«¯ã¢ãã
é¡ãåŸãããšãã§ãããâã¡ãã«âãã³ãºãã
ãªã«ã¢ãã³æš¹èãå©çšããæ¹æ³ã¯ã¢ããã³
ïŒMonahanïŒçã«ãããBiochemical and
Biophysical Research Communicationsã48ïŒ
1100ã1105ïŒ1972ïŒã«èšèŒãããŠãããåãã³ãº
ãããªã«ã¢ãã³ã䜿çšããæ¹æ³ã¯ãžãšã€ã»ãªããš
ãŒã«ïŒJ.RivierïŒçã«ããJournal of Medicinal
ChemistryïŒ1973ïŒVol.16ïŒ545â549ïŒã«èšèŒã
ããŠããã
ãã€ãŒã«ãæ³ã«æŒããåŠãäžæº¶æ§ããªããŒãå©çš
ããããšã奜ãŸããããå¿è«ä»ã®æ¹æ³ã§è£œé ãã
ããšãåºæ¥ããäŸãã°ãâã¡ãã«âãã³ãºãã
ãªã«ã¢ãã³æš¹èãããã¯ãã³ãºãããªã«ã¢ãã³æš¹
èçã®å¥ã®åºäœæ¯æäœã䜿çšããããšãã§ããã
ããã®æš¹èã䜿çšããããšãæå©ãªå Žåãããã
ãããã®æš¹èãçšããå Žåã«ã¯ãâæ«ç«¯ã¢ãã
é žãçŽæ¥æš¹èã«ä»çãããåŸãããããããã¯
HFäžã§æš¹èåºäœããåé¢ãããŠïŒ£âæ«ç«¯ã¢ãã
é¡ãåŸãããšãã§ãããâã¡ãã«âãã³ãºãã
ãªã«ã¢ãã³æš¹èãå©çšããæ¹æ³ã¯ã¢ããã³
ïŒMonahanïŒçã«ãããBiochemical and
Biophysical Research Communicationsã48ïŒ
1100ã1105ïŒ1972ïŒã«èšèŒãããŠãããåãã³ãº
ãããªã«ã¢ãã³ã䜿çšããæ¹æ³ã¯ãžãšã€ã»ãªããš
ãŒã«ïŒJ.RivierïŒçã«ããJournal of Medicinal
ChemistryïŒ1973ïŒVol.16ïŒ545â549ïŒã«èšèŒã
ããŠããã
æ¬çºæã®åºæ¬åœ¢ãã³ã¿ããããã®çš®ã
ã®èªå°äœ
ãå ¬ç¥ã®æ¹æ³ã§è£œé ããããšãã§ããããã®æ§ãª
èªå°äœã補é ããã«ã¯ãäžé£ã®åå¿ãé»å®³ããå¯
èœæ§ã®ããããããã®å®èœåºãä¿è·ããŠãããæ
æã®çæç©ãåŸãããã«ããããšãå¿ èŠã§ãã
ããäŸãã°ãã¢ã¹ãã©ã®ã³é žã®Î±âã«ã«ãã³é žåº
ãããã¯ãªã·ã³ã®Î±âã¢ããåºã¯ãèªå°äœã補é
ããæã«ã¯ä¿è·ããŠããå¿ èŠãããã
ãå ¬ç¥ã®æ¹æ³ã§è£œé ããããšãã§ããããã®æ§ãª
èªå°äœã補é ããã«ã¯ãäžé£ã®åå¿ãé»å®³ããå¯
èœæ§ã®ããããããã®å®èœåºãä¿è·ããŠãããæ
æã®çæç©ãåŸãããã«ããããšãå¿ èŠã§ãã
ããäŸãã°ãã¢ã¹ãã©ã®ã³é žã®Î±âã«ã«ãã³é žåº
ãããã¯ãªã·ã³ã®Î±âã¢ããåºã¯ãèªå°äœã補é
ããæã«ã¯ä¿è·ããŠããå¿ èŠãããã
äžè¿°ã®åŠããæ¬çºæã®æ¹æ³ãè¡ãã«ã¯ã¢ããåº
ãä¿è·åã¯å°éããããšãå¿ èŠã§ããããã«ãã
åå¿ãã³ã³ãããŒã«ãææã®çæç©ãåŸããæå¹
ã«äœ¿çšãåŸãé©åœãªã¢ããä¿è·åºãšã¯åŒ·å¡©åºæ§ã¢
ããåºãä¿è·ããããã®å¡©ã圢æã§ãããã®ãå
ã¯ãã³ãžã«ãªãã·ã«ã«ããã«åã³ïœâããã«ãªã
ã·ã«ã«ããã«çã®ãŠã¬ã¿ã³ä¿è·çœ®æåºããããå
åã®ã«ã«ããã·ã«åºç«¯ã§åå¿ããã¢ããé žã®Î±â
ã¢ããåºãä¿è·ããããã«ã¯ïœâããã«ãªãã·ã«
ã«ããã«ïŒ¬ïŒtBOCïŒåã¯ïœâã¢ãã«ãªãã·ã«ã«
ããã«ïŒAOCïŒãçšããããšã奜ãŸããããã
ã¯ãããã®BOCåã³AOCä¿è·åºã¯åå¿åŸæ¬¡ã®å·¥
çšïŒãã®å·¥çšã§æ¯ãαâã¢ããåºèªèº«ãåå¿ã
ãïŒã«å ç«ã€ãŠé žïŒäŸãã°ããªãã«ãªã«é ¢é žïŒã®
æ¯èŒçæž©åãªäœçšã§å®¹æã«é€ãããšãã§ãããã
ã®é žåŠçã¯ä»ã®åå¿æ§åŽéãä¿è·ããããã®åºã«
ã¯å¥ã«äœã®åœ±é¿ãäžããªããåŸã€ãŠã次ã®åå¿ã«
察ããŠÎ±âã¢ããåºãä¿è·ãããã€ããããåå
ã«ç¹ã«åœ±é¿ãäžããªãæ¡ä»¶äžã§åŸã«é€ãããšãã§
ãããã¹ãŠã®ç©è³ªãšã®åå¿ã«ããαâã¢ããåºã
ä¿è·ããããšãã§ãããšããããšã§ãããæ¯ãç©
質ã®äŸãšããŠã¯ã¢ããåºãã¢ã·ã«åãåŸãææ©ã«
ã«ãã³é žã®èªå°äœãæããããšãã§ããã
ãä¿è·åã¯å°éããããšãå¿ èŠã§ããããã«ãã
åå¿ãã³ã³ãããŒã«ãææã®çæç©ãåŸããæå¹
ã«äœ¿çšãåŸãé©åœãªã¢ããä¿è·åºãšã¯åŒ·å¡©åºæ§ã¢
ããåºãä¿è·ããããã®å¡©ã圢æã§ãããã®ãå
ã¯ãã³ãžã«ãªãã·ã«ã«ããã«åã³ïœâããã«ãªã
ã·ã«ã«ããã«çã®ãŠã¬ã¿ã³ä¿è·çœ®æåºããããå
åã®ã«ã«ããã·ã«åºç«¯ã§åå¿ããã¢ããé žã®Î±â
ã¢ããåºãä¿è·ããããã«ã¯ïœâããã«ãªãã·ã«
ã«ããã«ïŒ¬ïŒtBOCïŒåã¯ïœâã¢ãã«ãªãã·ã«ã«
ããã«ïŒAOCïŒãçšããããšã奜ãŸããããã
ã¯ãããã®BOCåã³AOCä¿è·åºã¯åå¿åŸæ¬¡ã®å·¥
çšïŒãã®å·¥çšã§æ¯ãαâã¢ããåºèªèº«ãåå¿ã
ãïŒã«å ç«ã€ãŠé žïŒäŸãã°ããªãã«ãªã«é ¢é žïŒã®
æ¯èŒçæž©åãªäœçšã§å®¹æã«é€ãããšãã§ãããã
ã®é žåŠçã¯ä»ã®åå¿æ§åŽéãä¿è·ããããã®åºã«
ã¯å¥ã«äœã®åœ±é¿ãäžããªããåŸã€ãŠã次ã®åå¿ã«
察ããŠÎ±âã¢ããåºãä¿è·ãããã€ããããåå
ã«ç¹ã«åœ±é¿ãäžããªãæ¡ä»¶äžã§åŸã«é€ãããšãã§
ãããã¹ãŠã®ç©è³ªãšã®åå¿ã«ããαâã¢ããåºã
ä¿è·ããããšãã§ãããšããããšã§ãããæ¯ãç©
質ã®äŸãšããŠã¯ã¢ããåºãã¢ã·ã«åãåŸãææ©ã«
ã«ãã³é žã®èªå°äœãæããããšãã§ããã
äžè¬ã«ãã¢ããåºã¯äžèšåŒã§ç€ºãããåºãå«ã
ååç©ãšã®åå¿ã«ããä¿è·ããããšãåºæ¥ãã
ååç©ãšã®åå¿ã«ããä¿è·ããããšãåºæ¥ãã
äžåŒã§ãã¯ã¢ããåºã次ã®ã«ãããªã³ã°åå¿
ã«é¢äžããããšãé²æ¢ãããã€ååãç Žå£ããã
ãšãªãé€å»ã§ããåºã§ããã°ããããã®ãããªåº
ãšããŠã¯é£œååã¯äžé£œåçŽéåã¯åå²éã¢ã«ã
ã«ã§ã奜ãŸããã¯ççŽ æ°ïŒâ10ã®ãã®ãã¢ãªãŒ
ã«ã奜ãŸããã¯ççŽ æ°ïŒâ15ã®ãã®ãã·ã¯ãã¢ã«
ãã«ã奜ãŸããã¯ççŽ æ°ïŒâïŒã®ãã®ãã¢ã«ã¢ã«
ãã«ã奜ãŸããã¯ççŽ æ°ïŒâ18ã®ãã®ãã¢ã«ã«ãª
ãŒã«ã奜ãŸããã¯ççŽ æ°ïŒâ18ã®ãã®ãåã¯ã€ãœ
ãã³ããã«çã®è€çŽ ç°åŒåºãããã
ã«é¢äžããããšãé²æ¢ãããã€ååãç Žå£ããã
ãšãªãé€å»ã§ããåºã§ããã°ããããã®ãããªåº
ãšããŠã¯é£œååã¯äžé£œåçŽéåã¯åå²éã¢ã«ã
ã«ã§ã奜ãŸããã¯ççŽ æ°ïŒâ10ã®ãã®ãã¢ãªãŒ
ã«ã奜ãŸããã¯ççŽ æ°ïŒâ15ã®ãã®ãã·ã¯ãã¢ã«
ãã«ã奜ãŸããã¯ççŽ æ°ïŒâïŒã®ãã®ãã¢ã«ã¢ã«
ãã«ã奜ãŸããã¯ççŽ æ°ïŒâ18ã®ãã®ãã¢ã«ã«ãª
ãŒã«ã奜ãŸããã¯ççŽ æ°ïŒâ18ã®ãã®ãåã¯ã€ãœ
ãã³ããã«çã®è€çŽ ç°åŒåºãããã
ã¢ãªãŒã«ãã¢ã«ã¢ã«ãã«åã³ã¢ã«ã«ãªãŒã«ã®å
åºã¯ççŽ æ°ïŒâçŽïŒã®ïŒçš®åã¯ãã以äžã®ã¢ã«ã
ã«ã«ããæŽã«çœ®æãããŠããŠãããããšããŠå¥œ
ãŸããåºã¯ïœâããã«ãïœâã¢ãã«ãããšãã«ïŒ
ããªã«ããã·ãªã«ãåã³ãã³ãžã«ã®ååºã§ããã
ç¹ã«å¥œãŸããç¹å®ã®ã¢ããä¿è·åºãšããŠã¯ãã³ãž
ã«ãªãã·ã«ã«ããã«ãããšãã«ç°ãïŒã€åã¯ãã
以äžã®Clåã¯Brçã®ããã²ã³ã§çœ®æãããŠãã
眮æãã³ãžã«ãªãã·ã«ã«ããã«ãããããã¡ãã
ã·çã®äœçŽã¢ã«ã³ãã·ãäœçŽã¢ã«ãã«ãïœâãã
ã«ãªãã·ã«ã«ããã«ãïœâã¢ãã«ãªãã·ã«ã«ãã
ã«ãã·ã¯ãããã·ã«ãªãã·ã«ã«ããã«ãããã«ãª
ãã·ã«ã«ããã«ãã¢ããã³ãã«ãªãã·ã«ã«ãã
ã«ããããšãã«ã€ãœããããã·ã«ãããã«çã§ã
ãã䜿çšå¯èœãªä»ã®ä¿è·åºãšããŠã¯ã€ãœãã³ãã
ã«ãªãã·ã«ã«ããã«ããã¿ãã€ã«ãïœâããªã«ã¹
ã«ããã«ããã«ãã«çã§ããã
åºã¯ççŽ æ°ïŒâçŽïŒã®ïŒçš®åã¯ãã以äžã®ã¢ã«ã
ã«ã«ããæŽã«çœ®æãããŠããŠãããããšããŠå¥œ
ãŸããåºã¯ïœâããã«ãïœâã¢ãã«ãããšãã«ïŒ
ããªã«ããã·ãªã«ãåã³ãã³ãžã«ã®ååºã§ããã
ç¹ã«å¥œãŸããç¹å®ã®ã¢ããä¿è·åºãšããŠã¯ãã³ãž
ã«ãªãã·ã«ã«ããã«ãããšãã«ç°ãïŒã€åã¯ãã
以äžã®Clåã¯Brçã®ããã²ã³ã§çœ®æãããŠãã
眮æãã³ãžã«ãªãã·ã«ã«ããã«ãããããã¡ãã
ã·çã®äœçŽã¢ã«ã³ãã·ãäœçŽã¢ã«ãã«ãïœâãã
ã«ãªãã·ã«ã«ããã«ãïœâã¢ãã«ãªãã·ã«ã«ãã
ã«ãã·ã¯ãããã·ã«ãªãã·ã«ã«ããã«ãããã«ãª
ãã·ã«ã«ããã«ãã¢ããã³ãã«ãªãã·ã«ã«ãã
ã«ããããšãã«ã€ãœããããã·ã«ãããã«çã§ã
ãã䜿çšå¯èœãªä»ã®ä¿è·åºãšããŠã¯ã€ãœãã³ãã
ã«ãªãã·ã«ã«ããã«ããã¿ãã€ã«ãïœâããªã«ã¹
ã«ããã«ããã«ãã«çã§ããã
æ¬çºæã®æ¹æ³ãè¡ãã«ã¯ãããããã¯éé¢Î±â
ã¢ããåºãä¿è·åœ¢Î±âã¢ããåºãå«ãååç©ãšå
å¿ãããããšã§åŸããããåå¿å³ã¡ã«ãããªã³ã°
ããããã«ã¯ãåå¿ãåããååç©ã®ã«ã«ããã·
ã«åºã掻æ§åãããŠãã«ã«ããã·ã«åºããããã
éã«çµåããŠããéé¢ã¢ããåºãšåå¿ãããã掻
æ§åããã«ã¯ãã«ã«ããã·ã«åºããšã¹ãã«ãç¡æ°Ž
ç©ãã¢ãžããé žã¯ãã©ã€ãçã®åå¿æ§åºã«å€ãã
ã°ããã
ã¢ããåºãä¿è·åœ¢Î±âã¢ããåºãå«ãååç©ãšå
å¿ãããããšã§åŸããããåå¿å³ã¡ã«ãããªã³ã°
ããããã«ã¯ãåå¿ãåããååç©ã®ã«ã«ããã·
ã«åºã掻æ§åãããŠãã«ã«ããã·ã«åºããããã
éã«çµåããŠããéé¢ã¢ããåºãšåå¿ãããã掻
æ§åããã«ã¯ãã«ã«ããã·ã«åºããšã¹ãã«ãç¡æ°Ž
ç©ãã¢ãžããé žã¯ãã©ã€ãçã®åå¿æ§åºã«å€ãã
ã°ããã
ã¢ããé
žæåã¯ã¢ããåºãšã«ã«ããã·ã«åºã®äž¡
è ãå«ãã§ãããããããã®åå¿äžéåžžäžæ¹ã®åº
ãåå¿ã«é¢äžãä»æ¹ã¯ä¿è·ãããŠãããã«ãããª
ã³ã°ã«å ç«ã€ãŠãåå¿ããããããã®Î±âåã¯æ«
端äœã®ã¢ããåºã«ä»ããŠããä¿è·åºã¯ãä»ã®ä¿è·
åºãäŸãã°ãªã·ã³ååã®Îµâã¢ããåºã«ä»ããŠã
ãåºã«å®è³ªçã«åœ±é¿ãäžããªãæ¡ä»¶äžã§é€å»ãã
ãããã®é€å»ããã«åœã€ãŠã®å¥œãŸããæ¹æ³ã¯é žã«
ããæž©åãªå æ°Žå解ã§ãããäŸãã°å®€æž©ã§ã®ããª
ãã«ãªã«é ¢é žãšã®åå¿ã«ãå æ°Žå解ã§ããã
è ãå«ãã§ãããããããã®åå¿äžéåžžäžæ¹ã®åº
ãåå¿ã«é¢äžãä»æ¹ã¯ä¿è·ãããŠãããã«ãããª
ã³ã°ã«å ç«ã€ãŠãåå¿ããããããã®Î±âåã¯æ«
端äœã®ã¢ããåºã«ä»ããŠããä¿è·åºã¯ãä»ã®ä¿è·
åºãäŸãã°ãªã·ã³ååã®Îµâã¢ããåºã«ä»ããŠã
ãåºã«å®è³ªçã«åœ±é¿ãäžããªãæ¡ä»¶äžã§é€å»ãã
ãããã®é€å»ããã«åœã€ãŠã®å¥œãŸããæ¹æ³ã¯é žã«
ããæž©åãªå æ°Žå解ã§ãããäŸãã°å®€æž©ã§ã®ããª
ãã«ãªã«é ¢é žãšã®åå¿ã«ãå æ°Žå解ã§ããã
äžè¿°äžé£ã®å·¥çšã«ããäžèšåŒã§ç€ºããããã³ã¿
ãããããçæããã
ãããããçæããã
ãã®ãã³ã¿ãããããåæ¬çºæã®ããªãããã
ã®åºæ¬åœ¢æŽ»æ§æ§é åäœãå«ãã§ãããåŒã®çœ®æ
ãã³ã¿ããããã¯å¿è«TYRåã³LYSã®æ«ç«¯ã¢ã
ãé žåºã¯äžè¿°ã®åŠãæŽã«çœ®æãããŠããŠããã
ãããã®çœ®æãã³ã¿ããããã¯äžèšåºæ¬åœ¢ãã³ã¿
ãããããé©åœãªè¬å€ãšåå¿ãããŠææã®èªå°äœ
ãåŸãããšãã§ããããã®çš®ã®ã¢ã·ã«åããšã¹ã
ã«åãã¢ããåçã®åå¿ã¯åšç¥ã®åå¿ã§ãããæŽ
ã«ãä»ã®ã¢ããé žé¡ãå³ã¡åºæ¬åœ¢ãã³ã¿ãããã
ååã®çååŠç掻æ§ã«åœ±é¿ãäžããªãã¢ããé žåº
ãããããéã«ä»å ããŠãããããã®ä»å åå¿ã¯
ãã³ã¿ããããã®åæãšåãé£ç¶åå¿ã§è¡ãããš
ãã§ããã
ã®åºæ¬åœ¢æŽ»æ§æ§é åäœãå«ãã§ãããåŒã®çœ®æ
ãã³ã¿ããããã¯å¿è«TYRåã³LYSã®æ«ç«¯ã¢ã
ãé žåºã¯äžè¿°ã®åŠãæŽã«çœ®æãããŠããŠããã
ãããã®çœ®æãã³ã¿ããããã¯äžèšåºæ¬åœ¢ãã³ã¿
ãããããé©åœãªè¬å€ãšåå¿ãããŠææã®èªå°äœ
ãåŸãããšãã§ããããã®çš®ã®ã¢ã·ã«åããšã¹ã
ã«åãã¢ããåçã®åå¿ã¯åšç¥ã®åå¿ã§ãããæŽ
ã«ãä»ã®ã¢ããé žé¡ãå³ã¡åºæ¬åœ¢ãã³ã¿ãããã
ååã®çååŠç掻æ§ã«åœ±é¿ãäžããªãã¢ããé žåº
ãããããéã«ä»å ããŠãããããã®ä»å åå¿ã¯
ãã³ã¿ããããã®åæãšåãé£ç¶åå¿ã§è¡ãããš
ãã§ããã
以äžãæ¬çºæãå®æœäŸã§å
·äœçã«èª¬æãããã
æ¬çºæã¯ãããã®å®æœäŸã«éå®ããããã®ã§ãª
ããå®æœäŸåã³æ¬æ现æžæ¬æã«æŒããŠã¯ãç¹ã«æ
瀺ããªãå Žåã¯éšã¯éééšã§ããã
æ¬çºæã¯ãããã®å®æœäŸã«éå®ããããã®ã§ãª
ããå®æœäŸåã³æ¬æ现æžæ¬æã«æŒããŠã¯ãç¹ã«æ
瀺ããªãå Žåã¯éšã¯éééšã§ããã
ãå®æœäŸ ïŒã
æ¬çºæã®ããªãããããåæããããã«ãäžèš
ç©è³ªãè³Œå ¥ããã
ç©è³ªãè³Œå ¥ããã
αâBOCââã°ã«ã¿ãã³ââãããããš
ãã«âãšã¹ã㫠αâBOCâεâïŒâã¯ãã«âãã³ãžã«ãªãã·
ã«ã«ããã«ââãªã·ã³ αâBOCââã¢ã¹ãã©ã®ã³ αâBOCââã€ãœãã€ã·ã³ αâBOCââïŒïŒïŒâãžã¯ãã«ãã³ãžã«â
âããã·ã³ äžèšè¬å€ã«æŒããŠãBOCã¯ïœâããã«ãªãã·
ã«ã«ããã«ã瀺ããã¢ããé žã®é次åå¿ã«éããŠ
çšããè©Šè¬ããžããã·ã«ã«ãŒããžã€ããããã«ãª
ã¬ã¹ã¢ãã³ïŒFluorescamineïŒåã³æš¹èãåžè²©å
ãè³Œå ¥ããã
ãã«âãšã¹ã㫠αâBOCâεâïŒâã¯ãã«âãã³ãžã«ãªãã·
ã«ã«ããã«ââãªã·ã³ αâBOCââã¢ã¹ãã©ã®ã³ αâBOCââã€ãœãã€ã·ã³ αâBOCââïŒïŒïŒâãžã¯ãã«ãã³ãžã«â
âããã·ã³ äžèšè¬å€ã«æŒããŠãBOCã¯ïœâããã«ãªãã·
ã«ã«ããã«ã瀺ããã¢ããé žã®é次åå¿ã«éããŠ
çšããè©Šè¬ããžããã·ã«ã«ãŒããžã€ããããã«ãª
ã¬ã¹ã¢ãã³ïŒFluorescamineïŒåã³æš¹èãåžè²©å
ãè³Œå ¥ããã
䜿çšããæš¹èã¯ç²åŸ200â400ã¡ãã·ãŠã®ããªã¹
ãã¬ã³ãžããã«ãã³ãŒã³æš¹èã§ãããïŒïŒ ã®ãžã
ãã«ãã³ãŒã³ãšæš¹èïŒïœåœã0.75ããªã¢ã«ã®ã¯ã
ã©ã€ããå«æããŠããã
ãã¬ã³ãžããã«ãã³ãŒã³æš¹èã§ãããïŒïŒ ã®ãžã
ãã«ãã³ãŒã³ãšæš¹èïŒïœåœã0.75ããªã¢ã«ã®ã¯ã
ã©ã€ããå«æããŠããã
ããªãããããåæããã«åœããïŒããªã¢ã«ã®
αâBOCâεâïŒâã¯ãã«ãã³ãžã«ãªãã·ã«ã«
ããã«ââãªã·ã³ãïŒããªã¢ã«ã®ããªãšãã«ã¢
ãã³ãå«ãç¡æ°Žã¢ã«ã³ãŒã«äž80âã§24æéåŠçã
ãŠïŒããªã¢ã«ã®ã¯ãã«ã¡ãã«åæš¹èã«ãšã¹ãã«å
ãããåŸãããçµåã¢ããé žæš¹èãæ¿Ÿéããç¡æ°Ž
ã¢ã«ã³ãŒã«ã§æŽæµããã€ä¹Ÿç¥ããã次ãã§ãæ®ã
ã®Î±âBOCã¢ããé žãåæ§ã«ããŠããããâæš¹
èã®ä¿è·è§£é€ãããαâã¢ããåºã«é 次çµåã
ããçŽæ¥çµåããŠããαâBOCââã°ã«ã¿ã
ã³ââãããããšãã«ãšã¹ãã«ä»¥å€ã¯åœéã®ãž
ã·ã¯ãããã·ã«ã«ãŒããžã€ãããçšããŠæ¬çºæã®
ããªãããããåæãããåã«ãããªã³ã°åå¿
åŸãå°éã®æš¹èããã«ãªã¬ã¹ã¢ãã³ã§è©Šéšããã
ãéœæ§è¢å ãšãªã€ãå Žåã«ã¯ã«ãããªã³ã°ã¯äžå®
å šã§ãããšããŠåäžã®ä¿è·åœ¢ã¢ããé žãçšããŠå
å¿ãç¹°è¿ãããæ°åã«ãããªã³ã°åå¿ãè¡ã€ãçµ
æãäžéäœãã³ã¿ããããâæš¹èãåŸãããã
αâBOCâεâïŒâã¯ãã«ãã³ãžã«ãªãã·ã«ã«
ããã«ââãªã·ã³ãïŒããªã¢ã«ã®ããªãšãã«ã¢
ãã³ãå«ãç¡æ°Žã¢ã«ã³ãŒã«äž80âã§24æéåŠçã
ãŠïŒããªã¢ã«ã®ã¯ãã«ã¡ãã«åæš¹èã«ãšã¹ãã«å
ãããåŸãããçµåã¢ããé žæš¹èãæ¿Ÿéããç¡æ°Ž
ã¢ã«ã³ãŒã«ã§æŽæµããã€ä¹Ÿç¥ããã次ãã§ãæ®ã
ã®Î±âBOCã¢ããé žãåæ§ã«ããŠããããâæš¹
èã®ä¿è·è§£é€ãããαâã¢ããåºã«é 次çµåã
ããçŽæ¥çµåããŠããαâBOCââã°ã«ã¿ã
ã³ââãããããšãã«ãšã¹ãã«ä»¥å€ã¯åœéã®ãž
ã·ã¯ãããã·ã«ã«ãŒããžã€ãããçšããŠæ¬çºæã®
ããªãããããåæãããåã«ãããªã³ã°åå¿
åŸãå°éã®æš¹èããã«ãªã¬ã¹ã¢ãã³ã§è©Šéšããã
ãéœæ§è¢å ãšãªã€ãå Žåã«ã¯ã«ãããªã³ã°ã¯äžå®
å šã§ãããšããŠåäžã®ä¿è·åœ¢ã¢ããé žãçšããŠå
å¿ãç¹°è¿ãããæ°åã«ãããªã³ã°åå¿ãè¡ã€ãçµ
æãäžéäœãã³ã¿ããããâæš¹èãåŸãããã
ãã®ãã³ã¿ããããâæš¹èã®åå²ãšä¿è·åºã®é€
å»ãïŒâ60åéç¡æ°Žããåæ°ŽçŽ ãçšããŠã±ã«ãå
å²è£ 眮ïŒPeninsula Lab.Inc.補ïŒã§è¡ãããã®å Ž
åã¹ã«ãã³ãžã€ãŒãšããŠããããâæš¹èïŒïœã«å¯Ÿ
ããŠ1.2mlã®ã¢ããœãŒã«ãçšãããããããæ··å
ç©ãåçµç空也ç¥ããç¡æ°ŽãšãŒãã«ã§æŽæµããã
ãã®ããããã1Né ¢é žäžïœâïŒããªâã²ã«
ïŒBioâGelïŒäžã«æ æããŠã¯ãããã°ã©ãåæã«
ä»ãããåŸãããããªããããã¯çŽåºŠ94ïŒ ã§äžèš
æ§é ãæããããšãåã€ãã
å»ãïŒâ60åéç¡æ°Žããåæ°ŽçŽ ãçšããŠã±ã«ãå
å²è£ 眮ïŒPeninsula Lab.Inc.補ïŒã§è¡ãããã®å Ž
åã¹ã«ãã³ãžã€ãŒãšããŠããããâæš¹èïŒïœã«å¯Ÿ
ããŠ1.2mlã®ã¢ããœãŒã«ãçšãããããããæ··å
ç©ãåçµç空也ç¥ããç¡æ°ŽãšãŒãã«ã§æŽæµããã
ãã®ããããã1Né ¢é žäžïœâïŒããªâã²ã«
ïŒBioâGelïŒäžã«æ æããŠã¯ãããã°ã©ãåæã«
ä»ãããåŸãããããªããããã¯çŽåºŠ94ïŒ ã§äžèš
æ§é ãæããããšãåã€ãã
ãè¬çè©ŠéšäŸã
äžèšããªããããã®æŽ»æ§åã³ç¹æ§ã調ã¹ããã
ã«ãå¥åº·ãªçåŸïŒãïŒé±éã®nuïŒnuããŠã¹ã®äž¡
æ§ã«ã€ããŠè©Šéšãè¡ã€ããããŠã¹ã¯BALBïŒïœ
èå°ïŒThyâ1.2è¡šé¢æåã瀺ãèžç·çŽ°èïŒã§é£Œ
è²ãããã€éåžžã®æ¡ä»¶äžã«ç¶æããããæè¡æž ã«
éããŠã¯ãæThyâ1.2è¡æž ãThyâïŒåæããŠ
ã¹ã§èª¿æŽããã
ã«ãå¥åº·ãªçåŸïŒãïŒé±éã®nuïŒnuããŠã¹ã®äž¡
æ§ã«ã€ããŠè©Šéšãè¡ã€ããããŠã¹ã¯BALBïŒïœ
èå°ïŒThyâ1.2è¡šé¢æåã瀺ãèžç·çŽ°èïŒã§é£Œ
è²ãããã€éåžžã®æ¡ä»¶äžã«ç¶æããããæè¡æž ã«
éããŠã¯ãæThyâ1.2è¡æž ãThyâïŒåæããŠ
ã¹ã§èª¿æŽããã
Thyâ1+T现èåã¯CR+B现èã®ååã®è©Šéšç®¡
äžèªå°ãè¡ããããè©Šéšç®¡äžã§åèžç·çŽ°è
ïŒProthymocyteïŒããã®èžç·çŽ°èã®ååèªå°ã
ã³ã ãåã³ãã€ã¹ïŒKomuroïŒBoyseïŒã«ããèš
èŒãããæ¹æ³ïŒLancetïŒïŒïŒ740ïŒ1973ïŒã«æºã
ãŠè¡ã€ãããã®æ¹æ³ã§ã¯Thyâ1.2ã®ç²åŸã现
èååã®ç®å®ãšããŠå©çšããŠãããäžæ¹ãè©Šéšç®¡
äžã§ã®CR-B现èå é§äœããã®CR+B现èãžã®å
åã®èªå°ãèžç·çŽ°èã®å Žåãšåæ§ã®æ¡ä»¶äžã§è¡ã€
ããããã®å Žååæã®åºæºãšããŠãããã®æäœå
ã³éå解æ§ã®è£äœãå€å°åéããçšåºŠã®éå¡è¢«ã
ããçŸã®èµ€è¡çãçµåããCR+B现èã®èœåãçš
ãããäžé£ç¶ãªçã®è¡æž ã¢ã«ããã³åŸé äžã§åå¥
ãããå¥åº·ãªnuïŒnuããŠã¹ã®èŸè现è矀ãäž¡å
é§äœïŒThyâ1-åã³CR-ïŒæºãšããŠçšããããã
ã¯åèšçŽ°è矀ã¯æ®ãã©åã¯å šãThyâ1+现èãå«
ãŸããããCR+现èã®æ°ã¯å°ãã§ãããšããçç±
ã«ããã
äžèªå°ãè¡ããããè©Šéšç®¡äžã§åèžç·çŽ°è
ïŒProthymocyteïŒããã®èžç·çŽ°èã®ååèªå°ã
ã³ã ãåã³ãã€ã¹ïŒKomuroïŒBoyseïŒã«ããèš
èŒãããæ¹æ³ïŒLancetïŒïŒïŒ740ïŒ1973ïŒã«æºã
ãŠè¡ã€ãããã®æ¹æ³ã§ã¯Thyâ1.2ã®ç²åŸã现
èååã®ç®å®ãšããŠå©çšããŠãããäžæ¹ãè©Šéšç®¡
äžã§ã®CR-B现èå é§äœããã®CR+B现èãžã®å
åã®èªå°ãèžç·çŽ°èã®å Žåãšåæ§ã®æ¡ä»¶äžã§è¡ã€
ããããã®å Žååæã®åºæºãšããŠãããã®æäœå
ã³éå解æ§ã®è£äœãå€å°åéããçšåºŠã®éå¡è¢«ã
ããçŸã®èµ€è¡çãçµåããCR+B现èã®èœåãçš
ãããäžé£ç¶ãªçã®è¡æž ã¢ã«ããã³åŸé äžã§åå¥
ãããå¥åº·ãªnuïŒnuããŠã¹ã®èŸè现è矀ãäž¡å
é§äœïŒThyâ1-åã³CR-ïŒæºãšããŠçšããããã
ã¯åèšçŽ°è矀ã¯æ®ãã©åã¯å šãThyâ1+现èãå«
ãŸããããCR+现èã®æ°ã¯å°ãã§ãããšããçç±
ã«ããã
ãã®çµæããã®ããªããããã¯ïŒŽãªã³ãçåã³
è£äœå容äœïŒCR+ïŒïŒ¢ãªã³ãçã®ååãèªå°ãã
ãšããç¹ã«æŒããŠãŠãããã³ãšåæ§ã®äœçšéžææ§
ã瀺ããããã®ãã³ã¿ããããã¯10nïœâ1ÎŒïœïŒ
mlã®æ¿åºŠç¯å²ã§Thyâ1+T现èã®ååãèªå°ãã
ã€10nïœâ1ÎŒïœïŒmlã®æ¿åºŠç¯å²ã§CR+B现èã®å
åãèªå°ããã
è£äœå容äœïŒCR+ïŒïŒ¢ãªã³ãçã®ååãèªå°ãã
ãšããç¹ã«æŒããŠãŠãããã³ãšåæ§ã®äœçšéžææ§
ã瀺ããããã®ãã³ã¿ããããã¯10nïœâ1ÎŒïœïŒ
mlã®æ¿åºŠç¯å²ã§Thyâ1+T现èã®ååãèªå°ãã
ã€10nïœâ1ÎŒïœïŒmlã®æ¿åºŠç¯å²ã§CR+B现èã®å
åãèªå°ããã
ãåèäŸ ïŒã
å®æœäŸïŒãšåæ§ã«ããŠåæããæªã æš¹èã«çµå
ããŠãããã³ã¿ããããé¡ããžã¯ãã«ã¡ã¿ã³äžã§
ããªãã«ãªã«é ¢é žã§åŠçããŠããã·ã³ã®ïœâ
BOCä¿è·åºãé€ãããåŸãããããããã次ã
ã§ç¡æ°Žé ¢é žã§ã¢ã·ã«åããæŽã«æš¹èåºæ¿ããåé¢
ãããã€ä¿è·åºããã¹ãŠHFãçšããŠåãé€ãäž
èšåŒã®ã¢ã·ã«åèªå°äœãåŸãã
ããŠãããã³ã¿ããããé¡ããžã¯ãã«ã¡ã¿ã³äžã§
ããªãã«ãªã«é ¢é žã§åŠçããŠããã·ã³ã®ïœâ
BOCä¿è·åºãé€ãããåŸãããããããã次ã
ã§ç¡æ°Žé ¢é žã§ã¢ã·ã«åããæŽã«æš¹èåºæ¿ããåé¢
ãããã€ä¿è·åºããã¹ãŠHFãçšããŠåãé€ãäž
èšåŒã®ã¢ã·ã«åèªå°äœãåŸãã
ãåèäŸ ïŒã
å®æœäŸïŒã®ãã³ã¿ããããé¡ã®ã¢ããåèªå°äœ
ãåŸãããã«ãåºæ¿ãšããŠãã³ãºãããªã«ã¢ãã³
ãçšããŠåè¿°J.Rivierçã®æ¹æ³ã«ããä¿è·ããã
ãã³ã¿ãããããåæããã次ãã§åŒåæ°ŽçŽ ãå©
çšããŠæš¹èåºæ¿ã«ä»çããŠããä¿è·ãã³ã¿ããã
ããéè£åé¢ããŠäžèšåŒã®ã¢ããåèªå°äœãåŸ
ãã
ãåŸãããã«ãåºæ¿ãšããŠãã³ãºãããªã«ã¢ãã³
ãçšããŠåè¿°J.Rivierçã®æ¹æ³ã«ããä¿è·ããã
ãã³ã¿ãããããåæããã次ãã§åŒåæ°ŽçŽ ãå©
çšããŠæš¹èåºæ¿ã«ä»çããŠããä¿è·ãã³ã¿ããã
ããéè£åé¢ããŠäžèšåŒã®ã¢ããåèªå°äœãåŸ
ãã
äžèšèªå°äœãåå®ããããã«ãèå±€ã¯ãããã°
ã©ãæ³åã³é»æ°æ³³åæ³ãçšãäžèšçµæãåŸãã
ã©ãæ³åã³é»æ°æ³³åæ³ãçšãäžèšçµæãåŸãã
èå±€ã¯ãããã°ã©ãæ³
è©ŠæïŒ30ÎŒïœ
ã·ãªã«ã²ã«ïŒããªã³ã¯ãã³ã¬ã©ã¹æ¿ãïŒÃ20
cmãåã0.25mmïŒ ïŒ²ïŒïœâãã¿ããŒã«ïŒããªãžã³ ïŒé ¢é žïŒHOAcïŒïŒæ°Ž30ïŒ15ïŒïŒïŒ12 ïŒé ¢é žãšãã«ïŒEtoAcïŒïŒããªãžã³ ïŒé ¢é žïŒæ°ŽïŒïŒïŒïŒïŒïŒïŒ ïŒé ¢é žãšãã«ïŒïœâãã¿ããŒã«ïŒé ¢é ž ïŒæ°ŽïŒïŒïŒïŒïŒïŒïŒ ã¹ãã¬ãŒè©Šè¬ïŒããŠãªè©Šè¬ããã³ãããªã³ åã³2 ååç©ã®çš®é¡ AcâTyrâAsnâIleâGlnâLys Tyr AsnâIleâGlnâLysâNH2 èå±€ã¯ãããã°ã©ãæ³ ïŒ²   0.47 0.87 0.54 0.48 0.87 0.37 é»æ°æ³³åæ³ é°æ¥µãžç§»åãããããã â1.35cm â6.60cm é»æ°æ³³åæ³ ã¯ãããã³ïŒmmåæ¿ŸçŽïŒ11.5cmÃ56.5mmïŒ è©ŠæïŒ100ÎŒïœ PH5.6ãããªãžã³âã¢ã»ããŒãç·©è¡æº¶æ¶²ã
100VãïŒæé ã¹ãã¬ãŒè©Šè¬ïŒããŠãªè©Šè¬åã³ãã³ãããªã³ åèäŸïŒã®ã¢ã»ãã«åãã³ã¿ãããããïŒïŒ ã
ãŠããŒïŒTwmoeyïŒæº¶æ¶²äž1ÎŒïœïŒmlã®æ¿åºŠã§çš
ããæãå®æœäŸïŒã®åºæ¬åœ¢ãã³ã¿ããããã«å¹æµ
ããæ倧åã³æå°æŽ»æ§åºŠã瀺ããã
cmãåã0.25mmïŒ ïŒ²ïŒïœâãã¿ããŒã«ïŒããªãžã³ ïŒé ¢é žïŒHOAcïŒïŒæ°Ž30ïŒ15ïŒïŒïŒ12 ïŒé ¢é žãšãã«ïŒEtoAcïŒïŒããªãžã³ ïŒé ¢é žïŒæ°ŽïŒïŒïŒïŒïŒïŒïŒ ïŒé ¢é žãšãã«ïŒïœâãã¿ããŒã«ïŒé ¢é ž ïŒæ°ŽïŒïŒïŒïŒïŒïŒïŒ ã¹ãã¬ãŒè©Šè¬ïŒããŠãªè©Šè¬ããã³ãããªã³ åã³2 ååç©ã®çš®é¡ AcâTyrâAsnâIleâGlnâLys Tyr AsnâIleâGlnâLysâNH2 èå±€ã¯ãããã°ã©ãæ³ ïŒ²   0.47 0.87 0.54 0.48 0.87 0.37 é»æ°æ³³åæ³ é°æ¥µãžç§»åãããããã â1.35cm â6.60cm é»æ°æ³³åæ³ ã¯ãããã³ïŒmmåæ¿ŸçŽïŒ11.5cmÃ56.5mmïŒ è©ŠæïŒ100ÎŒïœ PH5.6ãããªãžã³âã¢ã»ããŒãç·©è¡æº¶æ¶²ã
100VãïŒæé ã¹ãã¬ãŒè©Šè¬ïŒããŠãªè©Šè¬åã³ãã³ãããªã³ åèäŸïŒã®ã¢ã»ãã«åãã³ã¿ãããããïŒïŒ ã
ãŠããŒïŒTwmoeyïŒæº¶æ¶²äž1ÎŒïœïŒmlã®æ¿åºŠã§çš
ããæãå®æœäŸïŒã®åºæ¬åœ¢ãã³ã¿ããããã«å¹æµ
ããæ倧åã³æå°æŽ»æ§åºŠã瀺ããã
åèäŸïŒã®ã¢ããåãã³ã¿ããããã¯ãïŒïŒ
ã
ãŠããŒæº¶æ¶²äž1ÎŒïœïŒmlã®æ¿åºŠã§çšããæå®æœäŸ
ïŒã®åºæ¬åœ¢ãã³ã¿ããããã«å¹æµãã掻æ§ã瀺ã
ãã
ãŠããŒæº¶æ¶²äž1ÎŒïœïŒmlã®æ¿åºŠã§çšããæå®æœäŸ
ïŒã®åºæ¬åœ¢ãã³ã¿ããããã«å¹æµãã掻æ§ã瀺ã
ãã
ãåèäŸ ïŒã
å®æœäŸïŒã®æ¹æ³ã«åŸãåæããæš¹èã«ä»çããŠ
ããç¶æ ã®åºæ¬åœ¢ãã³ã¿ããããããšã¹ãã«äº€æ
æ¡ä»¶äžã¡ã¿ããŒã«äžã§ãããªãŠã ã¡ããã·ãã§ãš
ã¹ãã«äº€æããŠæš¹èããéè£åé¢ããããä¿è·åº
ããã¹ãŠé€å»ããŠäžèšåŒãæããã¹ãã«åçæç©
ãåŸãã
ããç¶æ ã®åºæ¬åœ¢ãã³ã¿ããããããšã¹ãã«äº€æ
æ¡ä»¶äžã¡ã¿ããŒã«äžã§ãããªãŠã ã¡ããã·ãã§ãš
ã¹ãã«äº€æããŠæš¹èããéè£åé¢ããããä¿è·åº
ããã¹ãŠé€å»ããŠäžèšåŒãæããã¹ãã«åçæç©
ãåŸãã
ãåèäŸ ïŒã
å®æœäŸïŒãšåæ§ã«ããŠåæããããããã®ãžãš
ãã«ã¢ãã³èªå°äœãåèäŸïŒã®ã¡ãã«ãšã¹ãã«å
åç©ãã補é ãããå³ã¡ãåèäŸïŒã®ã¡ãã«ãšã¹
ãã«ããžã¡ãã«ãã«ã ã¢ããäžã§ãžãšãã«ã¢ãã³
ãšåå¿ãããŠãäžèšåŒã®ãžã¢ãã眮æã¢ãããåŸ
ãã
ãã«ã¢ãã³èªå°äœãåèäŸïŒã®ã¡ãã«ãšã¹ãã«å
åç©ãã補é ãããå³ã¡ãåèäŸïŒã®ã¡ãã«ãšã¹
ãã«ããžã¡ãã«ãã«ã ã¢ããäžã§ãžãšãã«ã¢ãã³
ãšåå¿ãããŠãäžèšåŒã®ãžã¢ãã眮æã¢ãããåŸ
ãã
ãã®ãžãšãã«ã¢ãã³èªå°äœã¯ãå®æœäŸïŒã®æš¹è
åºæ¿ã«ä»çããŠããåºæ¬åœ¢ãã³ã¿ããããããžãš
ãã«ã¢ãã³ãšåå¿ãããŠæš¹èããåèšãã³ã¿ãã
ãããéè£åé¢ãããåå¿ãããåæ§ã«åŸãããš
ãã§ãããæš¹èããé€å»ããã€ä¿è·åºãé€ããŠåŸ
ãããçæç©ã¯ãžãšãã«ã¢ããèªå°äœã§ããã
åºæ¿ã«ä»çããŠããåºæ¬åœ¢ãã³ã¿ããããããžãš
ãã«ã¢ãã³ãšåå¿ãããŠæš¹èããåèšãã³ã¿ãã
ãããéè£åé¢ãããåå¿ãããåæ§ã«åŸãããš
ãã§ãããæš¹èããé€å»ããã€ä¿è·åºãé€ããŠåŸ
ãããçæç©ã¯ãžãšãã«ã¢ããèªå°äœã§ããã
ãåèäŸ ïŒã
æ¬åèäŸã§ã¯ãå®æœäŸïŒã®åºæ¬åœ¢ãã³ã¿ããã
ããèåãšãã«ãšåå¿ãããŠïŒ®âãšãã«ããã·ã³
èªå°äœãåŸãããã®åå¿ãè¡ãã«ããã€ãŠããªã·
ã³ã®Î±âã¢ããåºãεâïŒâã¯ãã«ãã³ãžã«ãªã
ã·ã«ã«ããã«åºã§ä¿è·ããTYRã®æ«ç«¯ã¢ããåº
ããžã¯ãã«ã¡ã¿ã³äžã§ããªãã«ãªã«é ¢é žãšåå¿ã
ããŠéé¢ãããããã®ä¿è·äžéäœãã¢ã«ãã«åæ¡
件äžã§ååŠéè«éã®èåãšãã«ãšåå¿ãããã
LYSαâã¢ããé žããäžèšä¿è·åºãé€å»ããŠäžèš
åŒãæãã眮æããªãããããåŸãã
ããèåãšãã«ãšåå¿ãããŠïŒ®âãšãã«ããã·ã³
èªå°äœãåŸãããã®åå¿ãè¡ãã«ããã€ãŠããªã·
ã³ã®Î±âã¢ããåºãεâïŒâã¯ãã«ãã³ãžã«ãªã
ã·ã«ã«ããã«åºã§ä¿è·ããTYRã®æ«ç«¯ã¢ããåº
ããžã¯ãã«ã¡ã¿ã³äžã§ããªãã«ãªã«é ¢é žãšåå¿ã
ããŠéé¢ãããããã®ä¿è·äžéäœãã¢ã«ãã«åæ¡
件äžã§ååŠéè«éã®èåãšãã«ãšåå¿ãããã
LYSαâã¢ããé žããäžèšä¿è·åºãé€å»ããŠäžèš
åŒãæãã眮æããªãããããåŸãã
ãåèäŸ ïŒã
æ¬åèäŸã§ã¯ãåèäŸïŒã®ãšãã«ã¢ããããªã
ãããã®ã¢ããåèªå°äœãåŸããå³ã¡ãåºæ¬åœ¢ã
ã³ã¿ãããããæš¹èåºæ¿ã«çµåããããŸãŸåèäŸ
ïŒã®åå¿ãè¡ããåºæ¿ããåé¢ãããã«ïŒ®âãšã
ã«èªå°äœãåŸãã次ãã§ãæš¹èåºæ¿ã«ä»çããŠã
ããã®äžéäœçæç©ããžã¡ãã«ãã«ã ã¢ãã溶åª
äžç¡æ°Žã¢ã³ã¢ãã¢ã§åŠçãæš¹èããåé¢ããäžèš
åŒã®ã¢ããããªãããããåŸãã
ãããã®ã¢ããåèªå°äœãåŸããå³ã¡ãåºæ¬åœ¢ã
ã³ã¿ãããããæš¹èåºæ¿ã«çµåããããŸãŸåèäŸ
ïŒã®åå¿ãè¡ããåºæ¿ããåé¢ãããã«ïŒ®âãšã
ã«èªå°äœãåŸãã次ãã§ãæš¹èåºæ¿ã«ä»çããŠã
ããã®äžéäœçæç©ããžã¡ãã«ãã«ã ã¢ãã溶åª
äžç¡æ°Žã¢ã³ã¢ãã¢ã§åŠçãæš¹èããåé¢ããäžèš
åŒã®ã¢ããããªãããããåŸãã
ãåèäŸ 11ã
æ¬åèäŸã§ã¯ãåèäŸïŒãšåæ§ã«ããŠåæãã
æš¹èåºæ¿ã«ä»çããŠãããŸãŸã®ã¢ã·ã«åãã³ã¿ã
ããããã¢ããååå¿æ¡ä»¶äžã§ç¡æ°Žã¢ã³ã¢ãã¢ãš
åå¿ãããŠãã®ååç©ãéé¢ãããä¿è·åºãé€å»
ããŠäžèšåŒã®ããªãããããåŸãã
æš¹èåºæ¿ã«ä»çããŠãããŸãŸã®ã¢ã·ã«åãã³ã¿ã
ããããã¢ããååå¿æ¡ä»¶äžã§ç¡æ°Žã¢ã³ã¢ãã¢ãš
åå¿ãããŠãã®ååç©ãéé¢ãããä¿è·åºãé€å»
ããŠäžèšåŒã®ããªãããããåŸãã
以äžãæ¬çºæã¯æŽ»æ§éšäœãšããŠåè¿°ã®ç¹ç°ãªã¢
ããé žæ§é åäœãæããæ°èŠãªããªãããããæ
äŸãããã®ã§ããããã®ããªããããã¯ãèžç·å
åæåTLåã³THYâïŒïŒÎžïŒã®ç²åŸã«ãã枬å®
ããããããªïŒŽâå é§äœçŽ°èãšïŒ¢çŽ°èã®èå¥ã®ç®
å®ã§ããè£äœã®å容äœã®ç²åŸã«ãã枬å®ãããã
ããªïŒ¢âå é§äœçŽ°èãšãååããããšãã§ããã
åŸã€ãŠãããããã¯èžç·æ©èœåã³å ç«åéãäŸã
ã°å 倩æ§èžç·æ¬ æã®æ²»çãã«æå¹ã§ããããã®ã
ãããã¯éåžžã«äœæ¿åºŠã§æŽ»æ§ã§ããã
ããé žæ§é åäœãæããæ°èŠãªããªãããããæ
äŸãããã®ã§ããããã®ããªããããã¯ãèžç·å
åæåTLåã³THYâïŒïŒÎžïŒã®ç²åŸã«ãã枬å®
ããããããªïŒŽâå é§äœçŽ°èãšïŒ¢çŽ°èã®èå¥ã®ç®
å®ã§ããè£äœã®å容äœã®ç²åŸã«ãã枬å®ãããã
ããªïŒ¢âå é§äœçŽ°èãšãååããããšãã§ããã
åŸã€ãŠãããããã¯èžç·æ©èœåã³å ç«åéãäŸã
ã°å 倩æ§èžç·æ¬ æã®æ²»çãã«æå¹ã§ããããã®ã
ãããã¯éåžžã«äœæ¿åºŠã§æŽ»æ§ã§ããã
æ¬çºæã¯ããã€ãã®å¥œãŸããå®æœæ
æ§ã«ã€ããŠ
説æããŠãããããããã®æ æ§ã«æ¬çºæãéå®ã
ãããã®ã§ãªãã
説æããŠãããããããã®æ æ§ã«æ¬çºæãéå®ã
ãããã®ã§ãªãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ã¢ããåºãä¿è·ãããŠããâãªã·ã³ãäžæº¶
æ§é«ååæš¹èã«ãšã¹ãã«åããŠå ±æçµåã§çµå
ããαâã¢ããä¿è·åºãâãªã·ã³éšããé€ããŠ
αâã¢ããä¿è·åœ¢ïŒ¬âã°ã«ã¿ãã³ãšåå¿ãããŠïŒ¬
âã°ã«ã¿ãã³ãâãªã·ã³âæš¹èãšçµåããã
âã°ã«ã¿ãã³éšããαâã¢ããä¿è·åºãé€ããŠÎ±
âã¢ããä¿è·åœ¢ïŒ¬âã€ãœãã€ã·ã³åã¯ïŒ¬âã¢ã©ã
ã³ãšåå¿ãããŠïŒ¬âã€ãœãã€ã·ã³åã¯ïŒ¬âã¢ã©ã
ã³ãâã°ã«ã¿ãã³ââãªã·ã³âæš¹èã«çµåã
ããαâã¢ããä¿è·åºãé€ããŠÎ±âã¢ããä¿è·åœ¢
âã¢ã¹ãã©ã®ã³åã¯ïŒ¬âã¢ã©ãã³ãšåå¿ãããŠ
âã¢ã¹ãã©ã®ã³åã¯ïŒ¬âã¢ã©ãã³ãâã€ãœã
ã€ã·ã³åã¯ïŒ¬âã¢ã©ãã³ââã°ã«ã¿ãã³ââ
ãªã·ã³âæš¹èã«çµåãããαâã¢ããä¿è·åºãé€
ããŠÎ±âã¢ããä¿è·åœ¢ïŒ¬âããã·ã³åã¯ïŒ¬âã¢ã©
ãã³ãšåå¿ãããŠïŒ¬âããã·ã³åã¯ïŒ¬âã¢ã©ãã³
ãâã¢ã¹ãã©ã®ã³åã¯ïŒ¬âã¢ã©ãã³ââã€ãœ
ãã€ã·ã³åã¯ïŒ¬âã¢ã©ãã³ââã°ã«ã¿ãã³â
âãªã·ã³âæš¹èã«çµåããã äžèšåŒãæããããããäžéäœã§ãã€ãŠã äžåŒã§ãR1ïŒR2åã³R3ã¯ã¢ããé žã®ä¿è·åºã§
ããããããäžéäœã圢æãã å šãŠã®ã¢ããä¿è·åºãåèšããããäžéäœãã
é€ãããããããé«ååæš¹èããåé¢ããŠäžèš
åŒã ã§è¡šããããã³ã¿ããããååç©ã®è£œé æ¹æ³ã ïŒ R1ã¯ïŒ¯âïŒïŒïŒâãžã¯ãã«ãã³ãžã«ïŒR2ã¯
εâïŒâã¯ãã«ãã³ãžã«ãªãã·ã«ã«ããã«ãåã³
R3ã¯ïœâããã«ãªãã·ã«ã«ããã«ã§ããããšã
ç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®ãã³ã¿
ããããååç©ã®è£œé æ¹æ³ã ïŒ åå¿ã¢ããé žé¡ã®åå¿æ§åŽéã¯åå¿æéäžä¿
è·ãããŠããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé ã«èšèŒã®æ¹æ³ã ïŒ é«ååæš¹èã¯ã»ã«ããŒã¹ãããªããã«ã¢ã«ã³
ãŒã«ãããªã¡ã¿ã¢ã¯ãªã¬ãŒããã¹ã«ãã³åããªã¹
ãã¬ã³åã³ã¹ãã¬ã³ãšãžããã«ãã³ãŒã³ãšã®ã¯ã
ã«ã¡ãã«å ±éåäœãããªã矀ããéžã°ããæš¹èã§
ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èš
èŒã®æ¹æ³ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85177877A | 1977-11-15 | 1977-11-15 | |
| US851778 | 1977-11-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6150999A JPS6150999A (ja) | 1986-03-13 |
| JPH0137400B2 true JPH0137400B2 (ja) | 1989-08-07 |
Family
ID=25311658
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1956878A Granted JPS5476522A (en) | 1977-11-15 | 1978-02-22 | Novel pentapeptides and manufacture |
| JP60111321A Granted JPS6150999A (ja) | 1977-11-15 | 1985-05-22 | ãã³ã¿ããããååç©ã®è£œé æ¹æ³ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1956878A Granted JPS5476522A (en) | 1977-11-15 | 1978-02-22 | Novel pentapeptides and manufacture |
Country Status (7)
| Country | Link |
|---|---|
| JP (2) | JPS5476522A (ja) |
| BE (1) | BE864122A (ja) |
| CA (1) | CA1105923A (ja) |
| CH (1) | CH640217A5 (ja) |
| DE (1) | DE2804567C2 (ja) |
| FR (1) | FR2408581A1 (ja) |
| SE (1) | SE446866B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215112A (en) * | 1979-03-14 | 1980-07-29 | Ortho Pharmaceutical Corporation | Tripeptides and methods |
| US4215111A (en) * | 1979-03-14 | 1980-07-29 | Ortho Pharmaceutical Corporation | Peptides having ubiquitin-like activity |
| DE2938420A1 (de) * | 1979-09-22 | 1981-04-09 | Hoechst Ag, 6000 Frankfurt | Neue peptide und verfahren zu ihrer herstellung |
| US4426324A (en) * | 1979-09-28 | 1984-01-17 | Hoffmann-La Roche Inc. | Immunopotentiating peptides |
| JPH0528542U (ja) * | 1991-04-03 | 1993-04-16 | åå·çœç çŠæ ªåŒäŒç€Ÿ | é£ç¶é³é çšãã³ã°ããºã« |
| ATE380342T1 (de) | 2001-05-07 | 2007-12-15 | Hipep Lab | Peptidimmobilisierte grundplatte und vefahren zum testen eines zielproteins unter verwendung derselben |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3864481A (en) * | 1972-12-14 | 1975-02-04 | St Lukes Hospital | Anti disease producing synthetic material for the prevention suppression and diagnosis of multiple sclerosis and method of treatment therefor |
| US4002602A (en) * | 1974-03-11 | 1977-01-11 | Gideon Goldstein | Ubiquitous immunopoietic polypeptide (UBIP) and methods |
| US4113858A (en) * | 1975-01-20 | 1978-09-12 | St. Luke's Hospital | Novel compounds, compositions and methods of their use |
-
1978
- 1978-01-27 SE SE7801031A patent/SE446866B/sv not_active IP Right Cessation
- 1978-02-03 DE DE2804567A patent/DE2804567C2/de not_active Expired
- 1978-02-08 CA CA296,484A patent/CA1105923A/en not_active Expired
- 1978-02-17 FR FR7804598A patent/FR2408581A1/fr active Granted
- 1978-02-20 BE BE185307A patent/BE864122A/xx not_active IP Right Cessation
- 1978-02-22 JP JP1956878A patent/JPS5476522A/ja active Granted
- 1978-02-24 CH CH206378A patent/CH640217A5/de not_active IP Right Cessation
-
1985
- 1985-05-22 JP JP60111321A patent/JPS6150999A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6149320B2 (ja) | 1986-10-29 |
| DE2804567A1 (de) | 1979-05-17 |
| JPS5476522A (en) | 1979-06-19 |
| FR2408581B1 (ja) | 1983-07-22 |
| SE446866B (sv) | 1986-10-13 |
| FR2408581A1 (fr) | 1979-06-08 |
| SE7801031L (sv) | 1979-05-16 |
| CA1105923A (en) | 1981-07-28 |
| DE2804567C2 (de) | 1986-01-16 |
| JPS6150999A (ja) | 1986-03-13 |
| CH640217A5 (en) | 1983-12-30 |
| BE864122A (fr) | 1978-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU625598B2 (en) | Peptides having t cell helper activity | |
| US4190646A (en) | Polypeptide compositions and methods | |
| JP2633481B2 (ja) | é µçŽ æµææ§å ç«èª¿ç¯ãããã | |
| FI92325C (fi) | MenetelmÀ tymopentiinianalogien valmistamiseksi | |
| US4261886A (en) | Peptides having thymopoietin-like activity | |
| US4002740A (en) | Tridecapeptide compositions and methods | |
| FI67692B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara tripeptider | |
| CA1146166A (en) | Peptides having ubiquitin-like activity | |
| US4190647A (en) | Polypeptides and methods | |
| CA1105925A (en) | Pentapeptide compositions and methods | |
| JPH0137400B2 (ja) | ||
| US4397842A (en) | Peptides having thymopoietin-like activity | |
| CA1120031A (en) | Tetrapeptides and methods | |
| IE49755B1 (en) | Peptides having thymopoietin-like activity,therapeutic compositions containing them,and process for their preparation | |
| US4258151A (en) | Pentapeptide modified resin | |
| US4258152A (en) | Pentapeptide modified resin | |
| HU205143B (en) | Process for producing peptides having t cell suppressor activity and pharmaceutical compositions comprising same | |
| GB1565032A (en) | Polypeptide compositions and methods for their manufacture | |
| US4232008A (en) | Tetrapeptides and methods | |
| GB1585736A (en) | Polypeptides and methods for their production | |
| FI96115B (fi) | MenetelmÀ peptidien valmistamiseksi, joilla on T-soluavustaja-aktiivisuutta |